0001326190-23-000047.txt : 20231107 0001326190-23-000047.hdr.sgml : 20231107 20231107160802 ACCESSION NUMBER: 0001326190-23-000047 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 231383736 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 alt-20230930x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-32587

ALTIMMUNE, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware		20-2726770
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

910 Clopper Road Suite 201S, Gaithersburg, Maryland		20878
(Address of Principal Executive Offices)		(Zip Code)

(240) 654-1450

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ALT	The NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	◻	Accelerated filer	◻
Non-accelerated filer	⌧	Smaller reporting company	⌧
		Emerging growth company	◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ⌧

As of November 3, 2023 there were 53,728,871 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

Table of Contents

ALTIMMUNE, INC.

TABLE OF CONTENTS


		Page

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022	1

	Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 (unaudited)	2

	Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2023 and 2022 (unaudited)	3

	Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 (unaudited)	5

	Notes to Consolidated Financial Statements (unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	20

Item 4.	Controls and Procedures	20


PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	20

Item 4.	Mine Safety Disclosures	21

Item 5.	Other Information	21

Item 6.	Exhibits	22

	Signatures	23

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ALTIMMUNE, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per-share amounts)


	September 30,		December 31,
	2023		2022
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	86,855	$	111,097
Restricted cash		41		34
Total cash, cash equivalents and restricted cash		86,896		111,131
Short-term investments		53,924		73,783
Accounts receivable		876		173
Income tax and R&D incentive receivables		3,653		2,368
Prepaid expenses and other current assets		7,615		5,358
Total current assets		152,964		192,813
Property and equipment, net		765		1,081
Indefinite-lived intangible asset		12,419		12,419
Other assets		425		615
Total assets	$	166,573	$	206,928
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,046	$	4,804
Accrued expenses and other current liabilities		8,825		12,250
Total current liabilities		11,871		17,054
Other long-term liabilities		4,305		4,581
Total liabilities		16,176		21,635
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 52,858,920 and 49,199,845 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		5		5
Additional paid-in capital		590,206		568,399
Accumulated deficit		(434,690)		(377,884)
Accumulated other comprehensive loss, net		(5,124)		(5,227)
Total stockholders’ equity		150,397		185,293
Total liabilities and stockholders’ equity	$	166,573	$	206,928

The accompanying notes are an integral part of the unaudited consolidated financial statements.

Table of Contents

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per-share amounts)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Revenues	$	362	$	2	$	389	$	42
Operating expenses:
Research and development		18,388		20,262		48,890		51,359
General and administrative		4,514		4,492		13,805		13,329
Total operating expenses		22,902		24,754		62,695		64,688
Loss from operations		(22,540)		(24,752)		(62,306)		(64,646)
Other income (expense):
Interest expense		(29)		(64)		(33)		(191)
Interest income		1,884		1,053		5,387		1,402
Other income (expense), net		14		50		146		185
Total other income (expense), net		1,869		1,039		5,500		1,396
Net loss before income taxes		(20,671)		(23,713)		(56,806)		(63,250)
Income tax expense (benefit)		—		(197)		—		(197)
Net loss		(20,671)		(23,516)		(56,806)		(63,053)
Other comprehensive income — unrealized gain (loss) on short-term investments		56		(143)		103		(263)
Comprehensive loss	$	(20,615)	$	(23,659)	$	(56,703)	$	(63,316)
Net loss per share, basic and diluted	$	(0.39)	$	(0.48)	$	(1.10)	$	(1.37)
Weighted-average common shares outstanding, basic and diluted		53,633,354		49,286,535		51,495,957		45,881,547

The accompanying notes are an integral part of the unaudited consolidated financial statements.

Table of Contents

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)


								Accumulated
				Additional				Other		Total
	Common Stock			Paid-In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity
Balance at December 31, 2022	49,199,845	$	5	$	568,399	$	(377,884)	$	(5,227)	$	185,293
Stock-based compensation	—		—		2,675		—		—		2,675
Exercise of stock options	19,303		—		61		—		—		61
Vesting of restricted stock awards including withholding, net	54,347		—		(484)		—		—		(484)
Issuance of common stock from Employee Stock Purchase Plan	13,215		—		135		—		—		135
Unrealized (loss) gain on short-term investments	—		—		—		—		126		126
Net loss	—		—		—		(20,074)		—		(20,074)
Balance at March 31, 2023	49,286,710	$	5	$	570,786	$	(397,958)	$	(5,101)	$	167,732
Stock-based compensation	—	$	—	$	2,786	$	—	$	—	$	2,786
Vesting of restricted stock awards including withholding, net	6,320		—		(16)		—		—		(16)
Issuance of common stock in at-the-market offerings, net	3,364,631		—		13,352		—		—		13,352
Unrealized (loss) gain on short-term investments	—		—		—		—		(79)		(79)
Net loss	—		—		—		(16,061)		—		(16,061)
Balance at June 30, 2023	52,657,661	$	5	$	586,908	$	(414,019)	$	(5,180)	$	167,714
Stock-based compensation	—	$	—	$	2,710	$	—	$	—	$	2,710
Vesting of restricted stock awards including withholding, net	1,261		—		(2)		—		—		(2)
Issuance of common stock in at-the-market offerings, net	171,653		—		510		—		—		510
Issuance of common stock from Employee Stock Purchase Plan	28,345		—		80		—		—		80
Unrealized loss on short-term investments	—		—		—		—		56		56
Net loss	—		—		—		(20,671)		—		(20,671)
Balance at September 30, 2023	52,858,920	$	5	$	590,206	$	(434,690)	$	(5,124)	$	150,397

The accompanying notes are an integral part of the unaudited consolidated financial statements.

Table of Contents

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)


								Accumulated
				Additional				Other		Total
	Common Stock			Paid-In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity
Balance at December 31, 2021	40,993,768	$	4	$	497,342	$	(293,171)	$	(5,040)	$	199,135
Stock-based compensation	—		—		2,033		—		—		2,033
Exercise of stock options	95,771		—		197		—		—		197
Vesting of restricted stock awards including withholding, net	17,568		—		(170)		—		—		(170)
Issuance of common stock from Employee Stock Purchase Plan	16,450		—		113		—		—		113
Issuance of common stock in at-the-market offerings, net	335,485		—		2,990		—		—		2,990
Issuance of common stock upon exercise of warrants	1,760,854		—		—		—		—		—
Net loss	—		—		—		(19,430)		—		(19,430)
Balance at March 31, 2022	43,219,896	$	4	$	502,505	$	(312,601)	$	(5,040)	$	184,868
Stock-based compensation	—	$	—	$	2,048	$	—	$	—	$	2,048
Exercise of stock options	152,913		—		403		—		—		403
Vesting of restricted stock awards including withholding, net	(5,865)		—		(80)		—		—		(80)
Issuance of common stock in at-the-market offerings, net	2,157,717		1		21,346		—		—		21,347
Issuance of common stock related to contingent consideration liability	847,444		—		6,176		—		—		6,176
Unrealized (loss) gain on short-term investments	—		—		—		—		(120)		(120)
Net loss	—		—		—		(20,107)		—		(20,107)
Balance at June 30, 2022	46,372,105	$	5	$	532,398	$	(332,708)	$	(5,160)	$	194,535
Stock-based compensation	—	$	—	$	2,128	$	—	$	—	$	2,128
Exercise of stock options	76,161		—		268		—		—		268
Vesting of restricted stock awards including withholding, net	(7,744)		—		(140)		—		—		(140)
Issuance of common stock in at-the-market offerings, net	2,711,013		—		31,829		—		—		31,829
Issuance of common stock from Employee Stock Purchase Plan	9,945		—		68		—		—		68
Other increase	157		—		—		—		—		—
Unrealized loss on short-term investments	—		—		—		—		(143)		(143)
Net loss	—		—		—		(23,516)		—		(23,516)
Balance at September 30, 2022	49,161,637	$	5	$	566,551	$	(356,224)	$	(5,303)	$	205,029

The accompanying notes are an integral part of the unaudited consolidated financial statements.

Table of Contents

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


	Nine Months Ended
	September 30,
	2023		2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(56,806)	$	(63,053)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration liability		—		86
Stock-based compensation expense		8,171		6,209
Depreciation and amortization		(1,413)		31
Loss on foreign currency exchange		(134)		(183)
Changes in operating assets and liabilities:
Accounts receivable		(704)		(204)
Prepaid expenses and other assets		(2,043)		3,204
Accounts payable		(1,758)		(615)
Accrued expenses and other liabilities		(3,306)		7,555
Income tax and R&D incentive receivables		(1,284)		1,690
Net cash used in operating activities		(59,277)		(45,280)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales and maturities of short-term investments		76,544		—
Purchases of short-term investments		(54,806)		(74,292)
Purchases of property and equipment, net		(47)		(88)
Net cash provided by (used in) investing activities		21,691		(74,380)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of deferred offering costs		(195)		—
Proceeds from issuance of common stock in at-the-market offerings, net		13,862		56,166
Proceeds from issuance of common stock from Employee Stock Purchase Plan		215		181
Payment of conditional economic incentive		(90)		—
Proceeds from exercises of stock options		61		868
Payments for tax withholding in share-based compensation		(502)		(391)
Net cash provided by financing activities		13,351		56,824
Net decrease in cash and cash equivalents and restricted cash		(24,235)		(62,836)
Cash, cash equivalents and restricted cash at beginning of period		111,131		190,335
Cash, cash equivalents and restricted cash at end of period	$	86,896	$	127,499

SUPPLEMENTAL NON-CASH ACTIVITIES:
Fair value of common stock retired in exchange for issuance of common stock warrant	$	—	$	6,176

The accompanying notes are an integral part of the unaudited consolidated financial statements.

Table of Contents

ALTIMMUNE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Business and Basis of Presentation

Nature of Business

Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.

The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (“HepTcell^TM”). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.

Basis of Presentation

The accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022 included in the Annual Report on Form 10-K which was filed with the SEC on February 28, 2023. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2023 or any future years or periods.

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accounting Policies

During the nine months ended September 30, 2023, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC, except for the recently adopted accounting standard for ASU No. 2016-13 as disclosed below.

Use of Estimates

The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not

Table of Contents

limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.

Short-term Investments

The Company’s short-term investments are comprised of U.S. Treasuries, corporate debt securities and certificates of deposit that have original maturities less than or equal to one year and are classified as available-for-sale (“AFS”) securities. Such securities are carried at estimated fair value, net of allowance for credit loss determined based on the Current Expected Credit Loss. Any unrealized holding gains or losses are reported as accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. In the event that the AFS security's fair value is below the amortized cost and (i) the Company intends to sell the AFS security and (ii) the AFS security is required to be sold before recovery of the loss, the AFS security's amortized cost base will be written down to its fair value and the loss will be recognized in the income statement. If the Company intends not to sell the AFS security and the AFS security is not required to be sold before recovery of the loss, the Company evaluates whether a portion of the unrealized loss is a result of credit loss. The portion of unrealized loss related to credit loss will be recorded as allowance for credit loss in the balance sheet with the corresponding credit loss in the income statement and the portion of unrealized loss not related to credit loss will be recognized in other comprehensive income (“OCI”). Dividend and interest income are recognized in other income when earned. The cost of securities sold is calculated using the specific identification method. The Company places all investments with government agencies, or corporate institutions whose debt is rated as investment grade. As of September 30, 2023, none of the unrealized losses on the Company’s short-term investments are a result of credit loss, and therefore, the unrealized losses were recognized in OCI.

Income Taxes

During the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax expense (benefit) for either of the three and nine months ended September 30, 2023 or 2022 due to a full valuation allowance. The Company calculates its quarterly income tax provision based on an estimated, annual effective tax rate applied to ordinary income (or loss) and other known items computed and recognized as they occur. The Company’s total provision is based on the United States statutory rate, increased by state and foreign taxes and reduced by a full valuation allowance on the Company’s deferred tax assets.

Recently adopted accounting pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”). ASU No. 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and any unrealized loss relating to available-for-sale debt securities to be recorded through an allowance for credit losses. The Company adopted this new accounting standard on January 1, 2023 using a modified retrospective method. Adoption of this update did not have a material impact on the Company’s financial statements and related disclosures.

3. Fair Value Measurements

The Company’s assets measured at fair value on a recurring basis as of September 30, 2023 consisted of the following (in thousands):


	Fair Value Measurement at September 30, 2023
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents - money market funds	$	82,102	$	82,102	$	—	$	—
Short-term investments		53,924		—		53,924		—
Total	$	136,026	$	82,102	$	53,924	$	—

Table of Contents

The Company’s assets measured at fair value on a recurring basis as of December 31, 2022 consisted of the following (in thousands):


	Fair Value Measurement at December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents - money market funds	$	105,794	$	105,794	$	—	$	—
Short-term investments		73,783		—		73,783		—
Total	$	179,577	$	105,794	$	73,783	$	—

Short-term investments have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third party pricing services or other market observable data (Level 2). The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value.

Short-term investments with quoted prices as of September 30, 2023 as shown below (in thousands):


	September 30, 2023
	Amortized Cost		Unrealized (Loss) Gain		Credit loss		Market Value
United States treasury securities	$	9,857	$	(7)	$	—	$	9,850
Commercial paper and corporate debt securities		33,328		(53)		—		33,275
Asset backed securities		2,937		(12)		—		2,925
Agency debt securities		7,886		(12)		—		7,874
Total	$	54,008	$	(84)	$	—	$	53,924

Short-term investments with quoted prices as of December 31, 2022 as shown below (in thousands):


	December 31, 2022
	Amortized Cost		Unrealized (Loss) Gain		Credit Loss		Market Value
United States treasury securities	$	15,868	$	(86)	$	—	$	15,782
Commercial paper and corporate debt securities		50,747		(71)		—		50,676
Asset backed securities		5,427		(35)		—		5,392
Agency debt securities		1,928		5		—		1,933
Total	$	73,970	$	(187)	$	—	$	73,783

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the nine months ended September 30, 2023 and year ended December 31, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis.

4. Operating Leases

The Company’s operating leases consist of leases for office and laboratory space in the United States, which expire in April 2025. Rent expense under the Company’s operating leases was $0.1 million and $0.4 million during the three and nine months ended September 30, 2023. During the three and nine months ended September 30, 2022, rent expense under the Company’s operating leases was $0.1 million and $0.4 million, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation.

Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.

Table of Contents

The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreements. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised.

The cash paid for operating lease liabilities for each of the nine months ended September 30, 2023 and 2022 was $0.4 million.

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):



	September 30, 2023			December 31, 2022
Operating lease obligations (see Note 5 and 6)	$	788		$	1,124
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)	$	424		$	596
Weighted-average remaining lease term (years)		1.6			2.3
Weighted-average discount rate		7.2	%		7.2	%

5. Accrued Expenses

Accrued expenses and other current liabilities consist of the following (in thousands):


	September 30, 2023		December 31, 2022
Accrued professional services	$	313	$	276
Accrued payroll and employee benefits		2,427		2,955
Accrued research and development		5,537		7,295
Lease obligation, current portion (see Note 4)		485		452
Excess tax refund payable		—		1,169
Accrued interest and other		63		103
Total accrued expenses and other current liabilities	$	8,825	$	12,250

6. Other Long-Term Liabilities

The Company’s other long-term liabilities are summarized as follows (in thousands):


	September 30, 2023		December 31, 2022
Research and development incentive credit	$	3,796	$	3,599
Lease obligation, long-term portion (see Note 4)		303		672
Conditional economic incentive grants		160		250
Other		46		60
Total other long-term liabilities	$	4,305	$	4,581

7. Common Stock

The Amended and Restated Certificate of Incorporation, as amended (“Charter”), authorizes the Company to issue 200,000,000 shares of common stock, par value $0.0001 per share. As of September 30, 2023, the Company had 52,858,920 shares of common stock issued and outstanding.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.

The Charter also authorizes the Company to issue 1,000,000 shares of preferred stock, par value $0.0001 per share. As of September 30, 2023, the Company had no shares of preferred stock issued and outstanding.

Table of Contents

At-the-Market Offerings

On February 28, 2023, the Company entered into an Equity Distribution Agreement (the “2023 Agreement”) with Evercore Group L.L.C., JMP Securities LLC and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”), with respect to an at-the-market offerings program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $150.0 million (the “Shares”) through the Sales Agents (the “2023 Offering”). All Shares offered and sold in the 2023 Offering will be issued pursuant to the Company’s Registration Statement on Form S-3ASR filed with the SEC on February 28, 2023, which was declared effective immediately, the prospectus supplement relating to the 2023 Offering filed with the SEC on February 28, 2023 and any applicable additional prospectus supplements related to the 2023 Offering that form a part of the Registration Statement. The Company capitalized approximately $0.2 million of other offering costs which will offset the proceeds received from the shares sold under the 2023 Agreement. During the nine months ended September 30, 2023, the Company sold 3,536,284 shares of common stock under the 2023 Agreement resulting in approximately $13.9 million in proceeds, net of $0.4 million commission and other offering costs. As of September 30, 2023, $135.7 million remained available to be sold under the 2023 Agreement. As of September 30, 2023, there was $0.2 million in deferred offering costs included in prepaid expenses and other current assets on the accompanying consolidated balance sheets.

On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “2021 Sales Agents”), with respect to an at-the-market offerings program under which the Company offered and sold shares of its common stock, having an aggregate offering price of up to $125.0 million (the “2021 Shares”) through the 2021 Sales Agents (the “2021 Offering”). All 2021 Shares offered and sold in the 2021 Offering were issued pursuant to the Company’s Registration Statement on Form S-3 filed with the SEC on December 31, 2020, which was declared effective on January 11, 2021, the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement. Under the 2021 Agreement, the Company sold 10,004,869 shares of common stock resulting in approximately $121.0 million in proceeds, net of $4.0 million commission and other offering costs. As of September 30, 2023, there were no remaining shares available under the 2021 Agreement.

Public Offering

On July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of common stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company.

The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, Derivatives and Hedging (“ASC 815”). The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the Pre-Funded Warrants were classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. On January 24, 2022, 760,870 of the Pre-Funded Warrants were exercised, resulting in the issuance of 760,870 shares of common stock. As of September 30, 2023, there were 869,566 remaining Pre-Funded Warrants unexercised. Subsequent to September 30, 2023, the remaining Pre-Funded Warrants were net cashless exercised, and currently no Pre-Funded Warrants remain available for exercise (see Note 11 Subsequent Events).

As of September 30, 2023, including the remaining 869,566 Pre-Funded Warrants, there were 1,015,166 outstanding warrants with a weighted-average exercise price of $0.66 and weighted-average contractual term of 0.2 years.

Table of Contents

8. Stock-Based Compensation

Stock Options

The Company’s stock option awards generally vest over four years and typically have a contractual life of ten years. As of September 30, 2023, there was $17.9 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 2.7 years. During the nine months ended September 30, 2023, the Company granted 1,760,026 stock options with a weighted average exercise price of $9.71 and per share weighted average grant date fair value of $7.86.

Information related to stock options outstanding as of September 30, 2023 is as follows:


				Weighted-Average
		Weighted-		Remaining
	Number of	Average		Contractual Term	Aggregate Intrinsic
	Stock Options	Exercise Price		(Years)	Value (In thousands)
Outstanding	5,079,329	$	9.31	5.9	$	239
Exercisable	2,260,984	$	8.81	5.8	$	200
Vested and expected to vest	4,769,311	$	9.28	5.9	$	235

Restricted Stock Units (RSUs)

During the nine months ended September 30, 2023, the Company granted 319,700 shares of RSUs with a weighted average grant date fair value of $13.20 which vest over four years. As of September 30, 2023, the Company had unvested RSUs of 618,543 shares with total unrecognized compensation expense of $5.1 million, which the Company expects to recognize over a weighted average period of approximately 2.7 years. During the nine months ended September 30, 2023, the Company issued 61,928 shares of unrestricted common stock as a result of the vesting of 100,642 RSUs net of 38,714 shares of common stock withheld to satisfy tax withholding obligations.

2019 Employee Stock Purchase Plan (ESPP)

Under the ESPP, employees purchased 41,560 shares for $0.2 million during the nine months ended September 30, 2023. During the nine months ended September 30, 2023 and 2022, the Company recognized compensation expense of $0.1 million and $0.2 million, respectively.

Stock-based Compensation Expense

Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2022 as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Research and development	$	1,164	$	743	$	3,560	$	2,024
General and administrative		1,546		1,385		4,611		4,185
Total	$	2,710	$	2,128	$	8,171	$	6,209

9. Net Loss Per Share

Because the Company has reported a net loss attributable to common stockholders for the nine months ended September 30, 2023 and 2022, basic and diluted net loss per share attributable to common stockholders in each period are the same.

Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic

Table of Contents

shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock.

Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, RSUs, common stock warrants, and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.

Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, RSUs, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:


	Nine Months Ended
	September 30,
	2023	2022
Common stock warrants	145,600	145,600
Common stock options	5,144,429	3,542,534
Restricted stock units	618,543	470,275
Restricted stock	—	13,454

10. Commitments and Contingencies

Spitfire Acquisition

In July 2019, the Company entered into the Spitfire merger agreement to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”). As part of the agreement, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. (the “Sales Milestone”) within ten years following the approval of a new drug application filed with the U. S. Food and Drug Administration (the “FDA”).

The contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, Contingencies. Accordingly, the Company will recognize the Sales Milestones when the contingency is probable and the amount can be reasonably estimated.

Litigation

The Company is a party in various contracts and subject to disputes, litigation, and potential claims arising in the ordinary course of business none of which are currently reasonably possible or probable of material loss.

11. Subsequent Events

On October 18, 2023, warrant holders exercised the remaining 869,566 Pre-Funded Warrants in a net cashless exercise and were issued 869,530 shares of common stock in a net cashless exercise (see Note 7 Common Stock).

In addition, in October 2023, 95,600 various other warrants with a weighted-average exercise price of $5.31 expired unexercised. The only remaining outstanding 50,000 warrants have an exercise price of $3.21 and have a maturity date of March 12, 2024.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our consolidated financial statements and related notes for the year ended December 31, 2022 included in our Annual Report on Form 10-K, which was filed with the SEC on February 28, 2023.

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “may,” “will,” “should,” “could,” “target,” “strategy,” “intend,” “project,” “guidance,” “likely,” “usually,” “potential,” or the negative of these words or variations of such words, similar expressions, or comparable terminology are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. A further list and description of risks, uncertainties and other factors that could cause actual results or events to differ materially from the forward-looking statements that we make is included in the cautionary statements herein and in our other filings with the SEC, including those set forth under Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Overview

Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (“NASH”). In addition, we are developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune” or the “Company” refer to the company and its subsidiaries.

Recent Business Update

On October 24, 2023, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation to the investigation of pemvidutide for the treatment of NASH.

Pemvidutide - IMPACT trial

On August 1, 2023 we announced that we enrolled the first subject in the Phase 2b IMPACT trial evaluating the safety and efficacy of pemvidutide in subjects with NASH. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. The biopsy-driven trial is expected to enroll approximately 190 subjects with and without diabetes randomized 1:2:2 to receive either 1.2 mg, 1.8 mg pemvidutide or placebo weekly for 48 weeks. The key efficacy endpoints are NASH resolution and fibrosis improvement after 24 weeks of treatment, with subjects followed for an additional 24 weeks to a total of 48 weeks for assessment of safety and additional biomarker responses. Top-line results from this trial are expected in the first quarter of 2025.

Table of Contents

Pemvidutide - MOMENTUM trial

On September 12, 2023, we announced the completion of dosing (last subject last dose) in our 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Topline results from this trial are expected in the fourth quarter of 2023.

On March 21, 2023 we announced the topline results from a Week 24 interim analysis of 160 subjects in our 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The MOMENTUM Phase 2 obesity trial is being conducted at 30 sites across the U.S. and enrolled 391 subjects with subjects randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. A pre-specified interim analysis was conducted after the first 160 subjects received up to 24 weeks of treatment.

At Week 24, subjects receiving pemvidutide achieved mean weight losses of 7.3%, 9.4% and 10.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.0% (efficacy estimand using a mixed model of repeated measures (“MMRM”) analysis). Approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at Week 24 at the 1.8 mg and 2.4 mg doses. Robust reductions in waist circumference (a measure of visceral fat) and serum lipids were also observed, and clinically meaningful reductions in blood pressure were achieved without clinically significant increases in heart rate.

On March 21, 2023, we also announced the results of the 12-week Phase 1b safety trial of pemvidutide in subjects with type 2 diabetes. The Phase 1b trial, which was conducted to evaluate the safety profile of pemvidutide in overweight and obese subjects with type 2 diabetes, was comprised of 54 subjects randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks.

Subjects receiving pemvidutide achieved mean weight losses of 4.4%, 6.1% and 7.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, over only 12 weeks of treatment, with the placebo group experiencing a mean weight gain of 0.8% (efficacy estimand using MMRM analysis).

HepTcell

On April 11, 2023, we announced the completion of enrollment in our Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (“CHB”). With the achievement of this milestone, data readout is planned for the first quarter of 2024.

The multicenter clinical trial, which is being conducted at 26 sites in North America, Europe and Southeast Asia, enrolled approximately 80 subjects with inactive CHB and low levels of hepatitis B surface antigen (“HBsAg”). Subjects were randomized 1:1 to HepTcell or placebo. The primary endpoint of the trial is clinical response, defined as a 1-log or greater reduction or clearance in HBsAg. Secondary endpoints include changes in the levels of hepatitis B virus (“HBV”) DNA, pre-genomic RNA and other markers of virologic response.

Table of Contents

Results of Operations

Comparison of the three months ended September 30, 2023 and 2022

The following table summarizes our results of operations for the three months ended September 30, 2023 and 2022 (in thousands):


	Three Months Ended
	September 30,
	2023		2022		Increase (Decrease)
Revenue	$	362	$	2	$	360	18,000	%
Operating expenses:
Research and development		18,388		20,262		(1,874)	(9)	%
General and administrative		4,514		4,492		22	0	%
Total operating expenses		22,902		24,754		(1,852)	(7)	%
Loss from operations		(22,540)		(24,752)		2,212	(9)	%
Other income (expense):
Interest expense		(29)		(64)		35	(55)	%
Interest income		1,884		1,053		831	79	%
Other income (expense), net		14		50		(36)	(72)	%
Total other income (expense), net		1,869		1,039		830	80	%
Net loss before income taxes		(20,671)		(23,713)		3,042	(13)	%
Income tax expense (benefit)		—		(197)		197	(100)
Net loss	$	(20,671)	$	(23,516)	$	2,845	(12)	%

Revenue

We have not generated any revenues from the sale of any products to date. Our revenue has historically consisted primarily of government and foundation grants and contracts that supported our efforts on specific research projects. We are closing out one such contract and any revenue reported during the three months ended September 30, 2023 and 2022 were for indirect rate adjustments.

Research and development expenses

Research and development expenses decreased by $1.9 million, or 9%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The decrease was primarily the result of:

●

a decrease of $3.5 million due to the development activities for pemvidutide primarily due to $5.5 million in expenses associated with the NAFLD trials and $1.3 million in expenses associated with Phase 1 safety trials, which were ongoing during the three months ended September 30, 2022, being substantially completed by March 31, 2023, and a $1.8 million reduction due to winding down of MOMENTUM Phase 2 trial, partially offset by $2.3 million in startup costs related to the IMPACT Phase 2b trial in NASH and a $2.8 million increase in net manufacturing expenses for production of Good Manufacturing Practice (“GMP”) drug substance materials;

●

a decrease of $0.2 million due to development activities for HepTcell; and

●

a net increase of $1.9 million due primarily to costs associated with non-project specific research and development costs such as $1.2 million for employee compensation including stock compensation, $0.2 million for contractors and $0.3 million for electronic document management system (“EDMS”) implementation and service costs.

General and administrative expenses

General and administrative expenses were consistent period-over-period at $4.5 million for the three months ended September 30, 2023 and 2022.

Table of Contents

Total other income (expense), net

Total other income (expense), net increased by $0.8 million or 80%, for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, primarily due to increase in interest income earned on our cash equivalents and short-term investments.

Income tax benefit

Income tax benefit of $0.2 million related to interest received and receivable on income tax refunds was recorded during the three months ended September 30, 2022. Other than the income tax benefit related to interest, we did not record an income tax expense (benefit) for the three months ended September 30, 2023 and 2022 due to a full valuation allowance.

Comparison of the nine months ended September 30, 2023 and 2022

The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022 (in thousands):


	Nine Months Ended
	September 30,
	2023		2022		Increase (Decrease)
Revenue	$	389	$	42	$	347	826	%
Operating expenses:
Research and development		48,890		51,359		(2,469)	(5)	%
General and administrative		13,805		13,329		476	4	%
Total operating expenses		62,695		64,688		(1,993)	(3)	%
Loss from operations		(62,306)		(64,646)		2,340	(4)	%
Other income (expense):
Interest expense		(33)		(191)		158	(83)	%
Interest income		5,387		1,402		3,985	284	%
Other income (expense), net		146		185		(39)	(21)	%
Total other income (expense), net		5,500		1,396		4,104	294	%
Net loss before income taxes		(56,806)		(63,250)		6,444	(10)	%
Income tax expense (benefit)		—		(197)		197	(100)
Net loss	$	(56,806)	$	(63,053)	$	6,247	(10)	%

Revenue

We have not generated any revenues from the sale of any products to date. Our revenue has historically consisted primarily of government and foundation grants and contracts that supported our efforts on specific research projects. We are closing out one such contract and any revenue reported during the nine months ended September 30, 2023 and 2022 were for indirect rate adjustments.

Research and development expenses

Research and development expenses decreased by $2.5 million, or 5%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The decrease was primarily the result of:

●

a decrease of $8.0 million due to the development activities for pemvidutide primarily due to $11.5 million in expenses associated with the NAFLD trials and $5.5 million in expenses associated with Phase 1 safety trials, which were ongoing during the nine months ended September 30, 2022, being substantially completed by March 31, 2023, partially offset by $4.1 million in startup costs related to the IMPACT Phase 2b trial in NASH, a $1.9 million increase in net manufacturing expenses for production of GMP drug substance materials and $3.0 million for the MOMENTUM Phase 2 trial, which began in September 2022 and completed dosing in September 2023; and

Table of Contents

●

a net increase of $5.5 million due primarily to costs associated with non-project specific research and development costs such as $4.2 million for employee compensation including stock compensation, $0.6 million for contractors and $0.8 million for EDMS implementation and service costs.

General and administrative expenses

General and administrative expenses increased by $0.5 million, or 4% for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, primarily due to a $0.4 million increase in stock compensation and other labor related expense.

Total other income (expense), net

Total other income (expense), net increased by $4.1 million or 294%, for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, primarily due to increase in interest income earned on our cash equivalents and short-term investments.

Income tax benefit

Income tax benefit of $0.2 million related to interest received and receivable on income tax refunds was recorded during the nine months ended September 30, 2022. Other than the income tax benefit related to interest, we did not record an income tax expense (benefit) for the nine months ended September 30, 2023 and 2022 due to a full valuation allowance.

Liquidity and Capital Resources

Overview

Our primary sources of cash during the nine months ended September 30, 2023 were from equity transactions, interest and dividends from our money market funds and short-term investments, and proceeds from maturity of our short-term investments. Our cash, cash equivalents, restricted cash and short-term investments were $140.8 million as of September 30, 2023. We believe, based on the operating cash requirements and capital expenditures expected for 2023 and 2024, our cash on hand as of September 30, 2023, together with expected cash receipts from our income tax refunds and R&D incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our September 30, 2023 consolidated financial statements.

We have not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales. In the past, our sources of revenue have consisted of grant revenues under our arrangements with BARDA for the development of NasoShield, MTEC for a clinical trial and development work on T-COVID, and to a lesser degree from other licensing arrangements. The MTEC contract was closed out in June 2021 and we are currently closing out the BARDA contract which was not renewed after December 31, 2021. We have incurred significant losses since we commenced operations. As of September 30, 2023, we had an accumulated deficit of $434.7 million. In addition, we have not generated positive cash flows from operations. We have had to rely on a variety of financing sources, including the issuance of debt and equity securities. As capital resources are consumed to fund our research and development activities, we may require additional capital beyond our currently anticipated amounts. In order to address our capital needs, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, government funding, and monetization of our existing programs through partnership arrangements or sales to third parties.

Sources of Liquidity

Public Offering

On July 16, 2020, we offered and sold (i) 3,369,564 shares of our common stock, at a price to the public of $23.00 per share, and (ii) Pre-Funded Warrants, at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of common stock, minus the exercise price of each Pre-

Table of Contents

Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of our common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to us. The gross proceeds of this offering were approximately $132.2 million, which includes the exercise in full of the underwriters’ option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately $124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by us. On January 24, 2022, 760,870 of the Pre-Funded Warrants were exercised, resulting in the issuance of 760,870 shares of common stock. The remaining 869,566 Pre-Funded Warrants were net cashless exercised on October 18, 2023, resulting in the issuance of 869,530 shares of common stock (see Note 11 Subsequent Events).

Shelf Registrations

On February 28, 2023, we filed a shelf registration statement on Form S-3ASR, which was declared effective immediately. This shelf registration allows us to offer and sell any amount of our common stock, preferred stock, debt securities, warrants, rights and units (the “2023 Shelf”) for a period of 3 years from effectiveness or until such determination that we no longer qualify as a well-known seasoned issuer.

On December 31, 2020, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on January 11, 2021. This shelf registration statement covered the offering, issuance and sale by us of up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”).

At-the-Market Offerings

On February 28, 2023, we entered an Equity Distribution Agreement (“the 2023 Agreement”) with Evercore Group L.L.C., JMP Securities LLC and B. Riley Securities, Inc., serving as sales agents, with respect to an at-the-market offerings program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $150.0 million. During the nine months ended September 30, 2023, we sold 3,536,284 shares of common stock under the 2023 Agreement resulting in approximately $13.9 million in net proceeds, and as of September 30, 2023, $135.7 million remained available to be sold under the 2023 Shelf.

On February 25, 2021, we entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents, with respect to an at-the-market offerings program under which we offered and sold shares of our common stock, having an aggregate offering price of up to $125.0 million. Under the 2021 Agreement, we sold 10,004,869 shares of common stock resulting in approximately $121.0 million in proceeds, net of $4.0 million commission and other offering costs. As of September 30, 2023, there were no remaining 2021 Shares available under the 2021 Agreement.

Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2023 and 2022:


	Nine Months Ended
	September 30,
(in thousands)	2023		2022
Net cash (used in) provided by:
Operating activities	$	(59,277)	$	(45,280)
Investing activities		21,691		(74,380)
Financing activities		13,351		56,824
Net decrease in cash and cash equivalents and restricted cash	$	(24,235)	$	(62,836)

Table of Contents

Operating Activities

Net cash used in operating activities was $59.3 million for the nine months ended September 30, 2023 compared to $45.3 million during the nine months ended September 30, 2022. The primary uses of cash from our operating activities include payments for labor and labor-related costs, professional fees, research and development costs associated with our clinical trials and other general corporate expenditures. The increase in cash used in operations of $14.0 million year over year is due to changes in working capital accounts of $20.7 million, partially offset by an increase in net loss as adjusted for non-cash items of $6.7 million.

Investing Activities

Net cash provided by investing activities was $21.7 million for the nine months ended September 30, 2023 compared to $74.4 million net cash used in during the nine months ended September 30, 2022. The net cash provided by investing activities during the nine months ended September 30, 2023 was primarily due to $76.5 million proceeds from sale and maturities of short-term investments, partially offset by $54.8 million purchase of short-term investments. The net cash used in investing activities during the nine months ended September 30, 2022 was primarily due to $74.3 million purchase of short-term investments.

Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2023 was $13.4 million compared to $56.8 million for the nine months ended September 30, 2022. The net cash provided by financing activities during the nine months ended September 30, 2023 was primarily the result of the receipt of $13.9 million in net proceeds from the issuance of common stock from our at-the-market offerings program, partially offset by $0.5 million payment for tax withholding obligations related to share-based compensation and $0.2 million payment for deferred offering costs. The net cash provided by financing activities during the nine months ended September 30, 2022 was primarily the result of the receipt of $56.2 million in proceeds from the issuance of common stock from our at-the-market offerings program and $0.9 million in proceeds from exercise of stock options, partially offset by $0.4 million payment for tax withholding obligations related to share-based compensation.

Current Resources

We have financed our operations to date principally through our equity offerings and proceeds from issuances of our preferred stock, common stock and warrants. As of September 30, 2023, we had $86.9 million of cash, cash equivalents and restricted cash and $53.9 million of short-term investments. Accordingly, management believes that we have sufficient capital to fund our plan of operations for at least a twelve-month period from the issuance date of our September 30, 2023 financial statements. However, in order to address our capital needs in the long-term, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, government funding, and monetization of our existing programs through partnership arrangements or sales to third parties.

Critical Accounting Estimates

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited consolidated financial statements, which have been prepared in accordance with U.S. GAAP and the rules and regulations of the SEC for interim financial reporting. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and the disclosure of contingent liabilities in our consolidated financial statements. We base our estimates and judgments on historical experience, knowledge of current conditions, and expectations of what could occur in the future given available information.

There have been no changes in our critical accounting policies and significant judgment and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, except for the recently adopted accounting standard for ASU No. 2016-13 as disclosed in Note 2. For more information regarding our critical accounting policies, we encourage you to read the discussion contained in Item 7 under the heading “Critical Accounting Estimates” and Note 2

Table of Contents

“Summary of Significant Accounting Policies” included in the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (“the “Exchange Act”) as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2023 identified in connection with the evaluation thereof by our management, including the Chief Executive Officer and Chief Financial Officer, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in various legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on February 28, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default upon Senior Securities

None.

Table of Contents

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits


		Exhibit Index

Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation, dated October 17, 2017 (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on October 18, 2017)

3.2		Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding a reverse stock split (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on September 13, 2018)

3.3		Certificate of Amendment to Amended and Restated Certificate of Incorporation regarding an increase in authorized shares (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 8-K filed on September 13, 2018)

3.4		Amended and Restated Bylaws of Altimmune, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 8-K filed on October 18, 2017)

31.1 †		Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

31.2 †		Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

32.1 †		Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

32.2 †		Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

†

This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

§	Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.


	ALTIMMUNE, INC.

Dated: November 7, 2023	By:	/s/ Vipin K. Garg
	Name:	Vipin K. Garg
	Title:	President and Chief Executive Officer (Principal Executive Officer)

Dated: November 7, 2023	By:	/s/ Richard Eisenstadt
	Name:	Richard Eisenstadt
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 alt-20230930xex31d1.htm EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Vipin K. Garg, certify that:

1.	I have reviewed this report on Form 10-Q of Altimmune, Inc. for the period ended September 30, 2023;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: November 7, 2023	/s/ Vipin K. Garg
	Name: Vipin K. Garg
	Title: President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 alt-20230930xex31d2.htm EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Richard Eisenstadt, certify that:

1.	I have reviewed this report on Form 10-Q of Altimmune, Inc. for the period ended September 30, 2023;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: November 7, 2023	/s/ Richard Eisenstadt
	Name: Richard Eisenstadt
	Title: Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 alt-20230930xex32d1.htm EX-32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the quarterly report on Form 10-Q of Altimmune, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Vipin K. Garg, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Vipin K. Garg
Vipin K. Garg
President and Chief Executive Officer
November 7, 2023

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-32.2 5 alt-20230930xex32d2.htm EX-32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the quarterly report on Form 10-Q of Altimmune, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Richard Eisenstadt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Richard Eisenstadt
Richard Eisenstadt
Chief Financial Officer
November 7, 2023

GRAPHIC 6 alt-20230930x10q002.jpg GRAPHIC begin 644 alt-20230930x10q002.jpg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end EX-101.SCH 7 alt-20230930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Fair Value Measurements - Schedule of Short Term Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Common Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Organization link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Operating Leases - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 alt-20230930_cal.xml EX-101.CAL EX-101.DEF 9 alt-20230930_def.xml EX-101.DEF EX-101.LAB 10 alt-20230930_lab.xml EX-101.LAB Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Quarterly Report Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Interactive Data Current Entity Interactive Data Current Security12b Title Title of 12(b) Security Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line1 Entity Address, Address Line One Entity Address Address Line2 Entity Address, Address Line Two Entity Address City Or Town Entity Address, City or Town Entity Address State Or Province Entity Address, State or Province Entity Address Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Transition Report Document Transition Report CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Assets Current [Abstract] Current assets: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Restricted Cash Current Restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Total cash, cash equivalents and restricted cash Short Term Investments Short-term investments Accounts Receivable Gross Current Accounts receivable Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes and research & development incentives. Income Taxes and Research & Development Incentive Receivable, Current Income tax and R&D incentive receivables Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Assets Current Total current assets Property Plant And Equipment Net Property and equipment, net Indefinite Lived Intangible Assets Excluding Goodwill Indefinite-lived intangible asset Other Assets Noncurrent Other assets Assets Total assets Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current [Abstract] Current liabilities: Accounts Payable Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Liabilities Current Total current liabilities Other Long Term Debt Noncurrent Other long-term liabilities Liabilities Total liabilities Commitments And Contingencies Commitments and contingencies (Note 10) Stockholders Equity [Abstract] Stockholders' equity: Common Stock Value Common stock, $0.0001 par value; 200,000,000 shares authorized; 52,858,920 and 49,199,845 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Additional Paid In Capital Additional paid-in capital Retained Earnings Accumulated Deficit Accumulated deficit Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss, net Stockholders Equity Ending Balance Beginning Balance Total stockholders' equity Liabilities And Stockholders Equity Total liabilities and stockholders' equity Common Stock Par Or Stated Value Per Share Common stock, par or stated value per share Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenues Revenues Operating Expenses [Abstract] Operating expenses: Research And Development Expense Research and development General And Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income Loss Loss from operations Nonoperating Income Expense [Abstract] Other income (expense): Interest Expense Interest expense Investment Income Interest Interest income Other Nonoperating Income Expense Other income (expense), net Nonoperating Income Expense Total other income (expense), net Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Net loss before income taxes Income Tax Expense Benefit Income tax expense (benefit) Income tax expense (benefit) Net Income Loss Net loss Net loss Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Other comprehensive income - unrealized gain (loss) on short-term investments Unrealized (loss) gain on short-term investments Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Comprehensive loss Net loss per share, basic Net loss per share, diluted Weighted Average Number Of Share Outstanding Basic And Diluted Weighted-average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding, diluted CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statement [Table] Statement [Table] Statement Equity Components [Axis] Equity Component Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Loss [Member] Statement [Line Items] Statement [Line Items] Shares Outstanding Ending Balance (in shares) Beginning Balance (in shares) Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation Stock Issued During Period Value Stock Options Exercised Exercise of stock options Stock Issued During Period Shares Stock Options Exercised Exercise of stock options (in shares) Restricted Stock Value Shares Issued Net Of Tax Withholdings Vesting of restricted stock awards including withholding, net Restricted Stock Shares Issued Net Of Shares For Tax Withholdings Unrestricted common stock Vesting of restricted stock awards including withholding, net (in shares) Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock from Employee Stock Purchase Plan Employees purchased, value Stock Issued During Period Shares Employee Stock Purchase Plans Issuance of common stock from Employee Stock Purchase Plan (in shares) Employees purchased, shares Stock Issued During Period Value New Issues Issuance of common stock in at the market offerings, net Stock Issued During Period Shares New Issues Issuance of common stock in at the market offerings, net (in shares) Shares of common stock sold Stock Issued During Period Value Acquisitions Issuance of common stock related to contingent consideration liability Stock Issued During Period Shares Acquisitions Issuance of common stock related to contingent consideration liability (in shares) Stock issued during period share exercise of warrants. Stock Issued During Period Share Exercise Of Warrants Issuance of common stock upon exercise of warrants (in shares) Stock Issued During Period, Shares, Other Other increase (in shares) CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided By Used In Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Profit Loss Net loss Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 Change in fair value of contingent consideration liability Share Based Compensation Stock-based compensation expense Depreciation, Amortization and Accretion, Net Depreciation and amortization Foreign Currency Transaction Gain Loss Unrealized Loss on foreign currency exchange Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued expenses and other liabilities The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid. Increase (Decrease) in Income Taxes and Tax Incentive Receivable Income tax and R&D incentive receivables Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds From Sale And Maturity Of Available For Sale Securities Proceeds from sales and maturities of short-term investments Payments To Acquire Available For Sale Securities Debt Purchases of short-term investments Payments To Acquire Property Plant And Equipment Purchases of property and equipment, net Net Cash Provided By Used In Investing Activities Net cash provided by (used in) investing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Payments of deferred offering costs. Payments Of Deferred Offering Costs Payments of deferred offering costs Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock in at-the-market offerings, net Proceeds from issuance of common stock in public offering Proceeds From Stock Plans Proceeds from issuance of common stock from Employee Stock Purchase Plan Payments of conditional economic incentive.. Payments of Conditional Economic Incentive Payment of conditional economic incentive Proceeds from Stock Options Exercised Proceeds from exercises of stock options Payment, Tax Withholding, Share-Based Payment Arrangement Payment for tax withholding in share-based compensation Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Net decrease in cash and cash equivalents and restricted cash Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] SUPPLEMENTAL NON-CASH ACTIVITIES: Conversion Of Stock Amount Converted1 Fair value of common stock retired in exchange for issuance of common stock warrant Nature of Business and Organization Nature of Business and Basis of Presentation. Nature of Business and Organization Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Leases Lessee Operating Leases [Text Block] Leases Accrued Expenses and Other Current Liabilities. Accounts Payable And Accrued Liabilities Disclosure [Text Block] Accrued Expenses Other Long-Term Liabilities Other Liabilities Disclosure [Text Block] Other Long-Term Liabilities Common Stock The entire disclosure of common stock. Common Stock [Text Block] Common Stock Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Commitments And Contingencies. Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events Subsequent Events [Text Block] Subsequent Events Use Of Estimates Use of Estimates Investment Policy [Text Block] Short-term Investments Income Tax Policy [Text Block] Income Taxes New Accounting Pronouncements Policy Policy [Text Block] Recently Adopted Accounting Pronouncements Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Schedule of Short Term Investments Schedule of supplemental balance sheet information related to Operating leases. Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block] Summary of Supplemental other Information Related to Operating Leases Balance Sheet Schedule Of Accrued Liabilities Table [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Other Noncurrent Liabilities Table [Text Block] Summary of Other Long-Term Liabilities Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Schedule Of Other Share Based Compensation Activity Table [Text Block] Schedule of Information Related to Stock Options Outstanding Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Stock-based Compensation Expense Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Money Market Funds [Member] Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value, Measurements, Recurring [Member] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Level 1 [Member] Level 2 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Investments Fair Value Disclosure Cash equivalents Assets Fair Value Disclosure Total Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] Financial Instrument [Axis] Financial Instruments United States Treasury Securities [Member] EX-101.PRE 11 alt-20230930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2023	Nov. 03, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Trading Symbol	ALT
Entity Registrant Name	ALTIMMUNE, INC.
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		53,728,871
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity File Number	001-32587
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2726770
Entity Address, Address Line One	910 Clopper Road
Entity Address, Address Line Two	Suite 201S
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	240
Local Phone Number	654-1450
Document Transition Report	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 86,855	$ 111,097
Restricted cash	41	34
Total cash, cash equivalents and restricted cash	86,896	111,131
Short-term investments	53,924	73,783
Accounts receivable	876	173
Income tax and R&D incentive receivables	3,653	2,368
Prepaid expenses and other current assets	7,615	5,358
Total current assets	152,964	192,813
Property and equipment, net	765	1,081
Indefinite-lived intangible asset	12,419	12,419
Other assets	425	615
Total assets	166,573	206,928
Current liabilities:
Accounts payable	3,046	4,804
Accrued expenses and other current liabilities	8,825	12,250
Total current liabilities	11,871	17,054
Other long-term liabilities	4,305	4,581
Total liabilities	16,176	21,635
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 52,858,920 and 49,199,845 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	5	5
Additional paid-in capital	590,206	568,399
Accumulated deficit	(434,690)	(377,884)
Accumulated other comprehensive loss, net	(5,124)	(5,227)
Total stockholders' equity	150,397	185,293
Total liabilities and stockholders' equity	$ 166,573	$ 206,928

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
CONSOLIDATED BALANCE SHEETS
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	52,858,920	49,199,845
Common stock, shares outstanding	52,858,920	49,199,845

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues	$ 362	$ 2	$ 389	$ 42
Operating expenses:
Research and development	18,388	20,262	48,890	51,359
General and administrative	4,514	4,492	13,805	13,329
Total operating expenses	22,902	24,754	62,695	64,688
Loss from operations	(22,540)	(24,752)	(62,306)	(64,646)
Other income (expense):
Interest expense	(29)	(64)	(33)	(191)
Interest income	1,884	1,053	5,387	1,402
Other income (expense), net	14	50	146	185
Total other income (expense), net	1,869	1,039	5,500	1,396
Net loss before income taxes	(20,671)	(23,713)	(56,806)	(63,250)
Income tax expense (benefit)		(197)		(197)
Net loss	(20,671)	(23,516)	(56,806)	(63,053)
Other comprehensive income - unrealized gain (loss) on short-term investments	56	(143)	103	(263)
Comprehensive loss	$ (20,615)	$ (23,659)	$ (56,703)	$ (63,316)
Net loss per share, basic	$ (0.39)	$ (0.48)	$ (1.10)	$ (1.37)
Net loss per share, diluted	$ (0.39)	$ (0.48)	$ (1.10)	$ (1.37)
Weighted-average common shares outstanding, basic	53,633,354	49,286,535	51,495,957	45,881,547
Weighted-average common shares outstanding, diluted	53,633,354	49,286,535	51,495,957	45,881,547

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2021	$ 4	$ 497,342	$ (293,171)	$ (5,040)	$ 199,135
Beginning Balance (in shares) at Dec. 31, 2021	40,993,768
Stock-based compensation		2,033			2,033
Exercise of stock options		197			197
Exercise of stock options (in shares)	95,771
Vesting of restricted stock awards including withholding, net		(170)			(170)
Vesting of restricted stock awards including withholding, net (in shares)	17,568
Issuance of common stock from Employee Stock Purchase Plan		113			113
Issuance of common stock from Employee Stock Purchase Plan (in shares)	16,450
Issuance of common stock in at the market offerings, net		2,990			2,990
Issuance of common stock in at the market offerings, net (in shares)	335,485
Issuance of common stock upon exercise of warrants (in shares)	1,760,854
Net loss			(19,430)		(19,430)
Ending Balance at Mar. 31, 2022	$ 4	502,505	(312,601)	(5,040)	184,868
Ending Balance (in shares) at Mar. 31, 2022	43,219,896
Beginning Balance at Dec. 31, 2021	$ 4	497,342	(293,171)	(5,040)	199,135
Beginning Balance (in shares) at Dec. 31, 2021	40,993,768
Unrealized (loss) gain on short-term investments					(263)
Net loss					(63,053)
Ending Balance at Sep. 30, 2022	$ 5	566,551	(356,224)	(5,303)	205,029
Ending Balance (in shares) at Sep. 30, 2022	49,161,637
Beginning Balance at Mar. 31, 2022	$ 4	502,505	(312,601)	(5,040)	184,868
Beginning Balance (in shares) at Mar. 31, 2022	43,219,896
Stock-based compensation		2,048			2,048
Exercise of stock options		403			403
Exercise of stock options (in shares)	152,913
Vesting of restricted stock awards including withholding, net		(80)			(80)
Vesting of restricted stock awards including withholding, net (in shares)	(5,865)
Issuance of common stock in at the market offerings, net	$ 1	21,346			21,347
Issuance of common stock in at the market offerings, net (in shares)	2,157,717
Issuance of common stock related to contingent consideration liability		6,176			6,176
Issuance of common stock related to contingent consideration liability (in shares)	847,444
Unrealized (loss) gain on short-term investments				(120)	(120)
Net loss			(20,107)		(20,107)
Ending Balance at Jun. 30, 2022	$ 5	532,398	(332,708)	(5,160)	194,535
Ending Balance (in shares) at Jun. 30, 2022	46,372,105
Stock-based compensation		2,128			2,128
Exercise of stock options		268			268
Exercise of stock options (in shares)	76,161
Vesting of restricted stock awards including withholding, net		(140)			(140)
Vesting of restricted stock awards including withholding, net (in shares)	(7,744)
Issuance of common stock from Employee Stock Purchase Plan		68			68
Issuance of common stock from Employee Stock Purchase Plan (in shares)	9,945
Issuance of common stock in at the market offerings, net		31,829			31,829
Issuance of common stock in at the market offerings, net (in shares)	2,711,013
Other increase (in shares)	157
Unrealized (loss) gain on short-term investments				(143)	(143)
Net loss			(23,516)		(23,516)
Ending Balance at Sep. 30, 2022	$ 5	566,551	(356,224)	(5,303)	205,029
Ending Balance (in shares) at Sep. 30, 2022	49,161,637
Beginning Balance at Dec. 31, 2022	$ 5	568,399	(377,884)	(5,227)	185,293
Beginning Balance (in shares) at Dec. 31, 2022	49,199,845
Stock-based compensation		2,675			2,675
Exercise of stock options		61			61
Exercise of stock options (in shares)	19,303
Vesting of restricted stock awards including withholding, net		(484)			(484)
Vesting of restricted stock awards including withholding, net (in shares)	54,347
Issuance of common stock from Employee Stock Purchase Plan		135			135
Issuance of common stock from Employee Stock Purchase Plan (in shares)	13,215
Unrealized (loss) gain on short-term investments				126	126
Net loss			(20,074)		(20,074)
Ending Balance at Mar. 31, 2023	$ 5	570,786	(397,958)	(5,101)	167,732
Ending Balance (in shares) at Mar. 31, 2023	49,286,710
Beginning Balance at Dec. 31, 2022	$ 5	568,399	(377,884)	(5,227)	185,293
Beginning Balance (in shares) at Dec. 31, 2022	49,199,845
Unrealized (loss) gain on short-term investments					103
Net loss					(56,806)
Ending Balance at Sep. 30, 2023	$ 5	590,206	(434,690)	(5,124)	150,397
Ending Balance (in shares) at Sep. 30, 2023	52,858,920
Beginning Balance at Mar. 31, 2023	$ 5	570,786	(397,958)	(5,101)	167,732
Beginning Balance (in shares) at Mar. 31, 2023	49,286,710
Stock-based compensation		2,786			2,786
Vesting of restricted stock awards including withholding, net		(16)			(16)
Vesting of restricted stock awards including withholding, net (in shares)	6,320
Issuance of common stock in at the market offerings, net		13,352			13,352
Issuance of common stock in at the market offerings, net (in shares)	3,364,631
Unrealized (loss) gain on short-term investments				(79)	(79)
Net loss			(16,061)		(16,061)
Ending Balance at Jun. 30, 2023	$ 5	586,908	(414,019)	(5,180)	167,714
Ending Balance (in shares) at Jun. 30, 2023	52,657,661
Stock-based compensation		2,710			2,710
Vesting of restricted stock awards including withholding, net		(2)			(2)
Vesting of restricted stock awards including withholding, net (in shares)	1,261
Issuance of common stock from Employee Stock Purchase Plan		80			80
Issuance of common stock from Employee Stock Purchase Plan (in shares)	28,345
Issuance of common stock in at the market offerings, net		510			510
Issuance of common stock in at the market offerings, net (in shares)	171,653
Unrealized (loss) gain on short-term investments				56	56
Net loss			(20,671)		(20,671)
Ending Balance at Sep. 30, 2023	$ 5	$ 590,206	$ (434,690)	$ (5,124)	$ 150,397
Ending Balance (in shares) at Sep. 30, 2023	52,858,920

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (56,806)	$ (63,053)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration liability		86
Stock-based compensation expense	8,171	6,209
Depreciation and amortization	(1,413)	31
Loss on foreign currency exchange	(134)	(183)
Changes in operating assets and liabilities:
Accounts receivable	(704)	(204)
Prepaid expenses and other assets	(2,043)	3,204
Accounts payable	(1,758)	(615)
Accrued expenses and other liabilities	(3,306)	7,555
Income tax and R&D incentive receivables	(1,284)	1,690
Net cash used in operating activities	(59,277)	(45,280)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales and maturities of short-term investments	76,544
Purchases of short-term investments	(54,806)	(74,292)
Purchases of property and equipment, net	(47)	(88)
Net cash provided by (used in) investing activities	21,691	(74,380)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of deferred offering costs	(195)
Proceeds from issuance of common stock in at-the-market offerings, net	13,862	56,166
Proceeds from issuance of common stock from Employee Stock Purchase Plan	215	181
Payment of conditional economic incentive	(90)
Proceeds from exercises of stock options	61	868
Payment for tax withholding in share-based compensation	(502)	(391)
Net cash provided by financing activities	13,351	56,824
Net decrease in cash and cash equivalents and restricted cash	(24,235)	(62,836)
Cash, cash equivalents and restricted cash at beginning of period	111,131	190,335
Cash, cash equivalents and restricted cash at end of period	$ 86,896	127,499
SUPPLEMENTAL NON-CASH ACTIVITIES:
Fair value of common stock retired in exchange for issuance of common stock warrant		$ 6,176

XML 18 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Organization

9 Months Ended

Sep. 30, 2023

Nature of Business and Organization

Nature of Business and Organization

1. Nature of Business and Basis of Presentation

Nature of Business

Basis of Presentation

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

Short-term Investments

Income Taxes

Recently adopted accounting pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2023

Fair Value Measurements

Fair Value Measurements

3. Fair Value Measurements

The Company’s assets measured at fair value on a recurring basis as of September 30, 2023 consisted of the following (in thousands):


	Fair Value Measurement at September 30, 2023
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents - money market funds	$	82,102	$	82,102	$	—	$	—
Short-term investments		53,924		—		53,924		—
Total	$	136,026	$	82,102	$	53,924	$	—

The Company’s assets measured at fair value on a recurring basis as of December 31, 2022 consisted of the following (in thousands):


	Fair Value Measurement at December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents - money market funds	$	105,794	$	105,794	$	—	$	—
Short-term investments		73,783		—		73,783		—
Total	$	179,577	$	105,794	$	73,783	$	—

Short-term investments with quoted prices as of September 30, 2023 as shown below (in thousands):


	September 30, 2023
	Amortized Cost		Unrealized (Loss) Gain		Credit loss		Market Value
United States treasury securities	$	9,857	$	(7)	$	—	$	9,850
Commercial paper and corporate debt securities		33,328		(53)		—		33,275
Asset backed securities		2,937		(12)		—		2,925
Agency debt securities		7,886		(12)		—		7,874
Total	$	54,008	$	(84)	$	—	$	53,924

Short-term investments with quoted prices as of December 31, 2022 as shown below (in thousands):


	December 31, 2022
	Amortized Cost		Unrealized (Loss) Gain		Credit Loss		Market Value
United States treasury securities	$	15,868	$	(86)	$	—	$	15,782
Commercial paper and corporate debt securities		50,747		(71)		—		50,676
Asset backed securities		5,427		(35)		—		5,392
Agency debt securities		1,928		5		—		1,933
Total	$	73,970	$	(187)	$	—	$	73,783

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Operating Leases

9 Months Ended

Sep. 30, 2023

Leases

Leases

4. Operating Leases

The cash paid for operating lease liabilities for each of the nine months ended September 30, 2023 and 2022 was $0.4 million.

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):



	September 30, 2023			December 31, 2022
Operating lease obligations (see Note 5 and 6)	$	788		$	1,124
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)	$	424		$	596
Weighted-average remaining lease term (years)		1.6			2.3
Weighted-average discount rate		7.2	%		7.2	%

XML 22 R11.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2023

Accrued Expenses and Other Current Liabilities.

Accrued Expenses

5. Accrued Expenses

Accrued expenses and other current liabilities consist of the following (in thousands):


	September 30, 2023		December 31, 2022
Accrued professional services	$	313	$	276
Accrued payroll and employee benefits		2,427		2,955
Accrued research and development		5,537		7,295
Lease obligation, current portion (see Note 4)		485		452
Excess tax refund payable		—		1,169
Accrued interest and other		63		103
Total accrued expenses and other current liabilities	$	8,825	$	12,250

XML 23 R12.htm IDEA: XBRL DOCUMENT

Other Long-Term Liabilities

9 Months Ended

Sep. 30, 2023

Other Long-Term Liabilities

Other Long-Term Liabilities

6. Other Long-Term Liabilities

The Company’s other long-term liabilities are summarized as follows (in thousands):


	September 30, 2023		December 31, 2022
Research and development incentive credit	$	3,796	$	3,599
Lease obligation, long-term portion (see Note 4)		303		672
Conditional economic incentive grants		160		250
Other		46		60
Total other long-term liabilities	$	4,305	$	4,581

XML 24 R13.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended

Sep. 30, 2023

Common Stock

Common Stock

7. Common Stock

At-the-Market Offerings

Public Offering

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2023

Stock-Based Compensation

Stock-Based Compensation

8. Stock-Based Compensation

Stock Options

Information related to stock options outstanding as of September 30, 2023 is as follows:


				Weighted-Average
		Weighted-		Remaining
	Number of	Average		Contractual Term	Aggregate Intrinsic
	Stock Options	Exercise Price		(Years)	Value (In thousands)
Outstanding	5,079,329	$	9.31	5.9	$	239
Exercisable	2,260,984	$	8.81	5.8	$	200
Vested and expected to vest	4,769,311	$	9.28	5.9	$	235

Restricted Stock Units (RSUs)

2019 Employee Stock Purchase Plan (ESPP)

Stock-based Compensation Expense


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Research and development	$	1,164	$	743	$	3,560	$	2,024
General and administrative		1,546		1,385		4,611		4,185
Total	$	2,710	$	2,128	$	8,171	$	6,209

XML 26 R15.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

9 Months Ended

Sep. 30, 2023

Net Loss Per Share

Net Loss Per Share

9. Net Loss Per Share


	Nine Months Ended
	September 30,
	2023	2022
Common stock warrants	145,600	145,600
Common stock options	5,144,429	3,542,534
Restricted stock units	618,543	470,275
Restricted stock	—	13,454

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments And Contingencies.

Commitments and Contingencies

10. Commitments and Contingencies

Spitfire Acquisition

Litigation

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2023

Subsequent Events

Subsequent Events

11. Subsequent Events

XML 29 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2023
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.
Short-term Investments	Short-term Investments The Company’s short-term investments are comprised of U.S. Treasuries, corporate debt securities and certificates of deposit that have original maturities less than or equal to one year and are classified as available-for-sale (“AFS”) securities. Such securities are carried at estimated fair value, net of allowance for credit loss determined based on the Current Expected Credit Loss. Any unrealized holding gains or losses are reported as accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. In the event that the AFS security's fair value is below the amortized cost and (i) the Company intends to sell the AFS security and (ii) the AFS security is required to be sold before recovery of the loss, the AFS security's amortized cost base will be written down to its fair value and the loss will be recognized in the income statement. If the Company intends not to sell the AFS security and the AFS security is not required to be sold before recovery of the loss, the Company evaluates whether a portion of the unrealized loss is a result of credit loss. The portion of unrealized loss related to credit loss will be recorded as allowance for credit loss in the balance sheet with the corresponding credit loss in the income statement and the portion of unrealized loss not related to credit loss will be recognized in other comprehensive income (“OCI”). Dividend and interest income are recognized in other income when earned. The cost of securities sold is calculated using the specific identification method. The Company places all investments with government agencies, or corporate institutions whose debt is rated as investment grade. As of September 30, 2023, none of the unrealized losses on the Company’s short-term investments are a result of credit loss, and therefore, the unrealized losses were recognized in OCI.
Income Taxes	Income Taxes During the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax expense (benefit) for either of the three and nine months ended September 30, 2023 or 2022 due to a full valuation allowance. The Company calculates its quarterly income tax provision based on an estimated, annual effective tax rate applied to ordinary income (or loss) and other known items computed and recognized as they occur. The Company’s total provision is based on the United States statutory rate, increased by state and foreign taxes and reduced by a full valuation allowance on the Company’s deferred tax assets.
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”). ASU No. 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and any unrealized loss relating to available-for-sale debt securities to be recorded through an allowance for credit losses. The Company adopted this new accounting standard on January 1, 2023 using a modified retrospective method. Adoption of this update did not have a material impact on the Company’s financial statements and related disclosures.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for investment in financial asset.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Measurements

Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis

The Company’s assets measured at fair value on a recurring basis as of September 30, 2023 consisted of the following (in thousands):


	Fair Value Measurement at September 30, 2023
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents - money market funds	$	82,102	$	82,102	$	—	$	—
Short-term investments		53,924		—		53,924		—
Total	$	136,026	$	82,102	$	53,924	$	—

The Company’s assets measured at fair value on a recurring basis as of December 31, 2022 consisted of the following (in thousands):


	Fair Value Measurement at December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents - money market funds	$	105,794	$	105,794	$	—	$	—
Short-term investments		73,783		—		73,783		—
Total	$	179,577	$	105,794	$	73,783	$	—

Schedule of Short Term Investments

Short-term investments with quoted prices as of September 30, 2023 as shown below (in thousands):


	September 30, 2023
	Amortized Cost		Unrealized (Loss) Gain		Credit loss		Market Value
United States treasury securities	$	9,857	$	(7)	$	—	$	9,850
Commercial paper and corporate debt securities		33,328		(53)		—		33,275
Asset backed securities		2,937		(12)		—		2,925
Agency debt securities		7,886		(12)		—		7,874
Total	$	54,008	$	(84)	$	—	$	53,924

Short-term investments with quoted prices as of December 31, 2022 as shown below (in thousands):


	December 31, 2022
	Amortized Cost		Unrealized (Loss) Gain		Credit Loss		Market Value
United States treasury securities	$	15,868	$	(86)	$	—	$	15,782
Commercial paper and corporate debt securities		50,747		(71)		—		50,676
Asset backed securities		5,427		(35)		—		5,392
Agency debt securities		1,928		5		—		1,933
Total	$	73,970	$	(187)	$	—	$	73,783

XML 31 R20.htm IDEA: XBRL DOCUMENT

Operating Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases

Summary of Supplemental other Information Related to Operating Leases Balance Sheet

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):



	September 30, 2023			December 31, 2022
Operating lease obligations (see Note 5 and 6)	$	788		$	1,124
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)	$	424		$	596
Weighted-average remaining lease term (years)		1.6			2.3
Weighted-average discount rate		7.2	%		7.2	%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2023

Accrued Expenses and Other Current Liabilities.

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	September 30, 2023		December 31, 2022
Accrued professional services	$	313	$	276
Accrued payroll and employee benefits		2,427		2,955
Accrued research and development		5,537		7,295
Lease obligation, current portion (see Note 4)		485		452
Excess tax refund payable		—		1,169
Accrued interest and other		63		103
Total accrued expenses and other current liabilities	$	8,825	$	12,250

XML 33 R22.htm IDEA: XBRL DOCUMENT

Other Long-Term Liabilities (Tables)

9 Months Ended

Sep. 30, 2023

Other Long-Term Liabilities

Summary of Other Long-Term Liabilities

The Company’s other long-term liabilities are summarized as follows (in thousands):


	September 30, 2023		December 31, 2022
Research and development incentive credit	$	3,796	$	3,599
Lease obligation, long-term portion (see Note 4)		303		672
Conditional economic incentive grants		160		250
Other		46		60
Total other long-term liabilities	$	4,305	$	4,581

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Stock-Based Compensation

Schedule of Information Related to Stock Options Outstanding

Information related to stock options outstanding as of September 30, 2023 is as follows:


				Weighted-Average
		Weighted-		Remaining
	Number of	Average		Contractual Term	Aggregate Intrinsic
	Stock Options	Exercise Price		(Years)	Value (In thousands)
Outstanding	5,079,329	$	9.31	5.9	$	239
Exercisable	2,260,984	$	8.81	5.8	$	200
Vested and expected to vest	4,769,311	$	9.28	5.9	$	235

Schedule of Stock-based Compensation Expense


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Research and development	$	1,164	$	743	$	3,560	$	2,024
General and administrative		1,546		1,385		4,611		4,185
Total	$	2,710	$	2,128	$	8,171	$	6,209

XML 35 R24.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Net Loss Per Share

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Nine Months Ended
	September 30,
	2023	2022
Common stock warrants	145,600	145,600
Common stock options	5,144,429	3,542,534
Restricted stock units	618,543	470,275
Restricted stock	—	13,454

XML 36 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Summary of Significant Accounting Policies
Income tax expense (benefit)	$ 197	$ 197

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	$ 53,924	$ 73,783
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments		73,783
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	53,924
Total	136,026	179,577
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	82,102	105,794
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Short-term investments	53,924
Total	53,924	73,783
Money Market Funds [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	82,102	105,794
Money Market Funds [Member] \| Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 82,102	$ 105,794

XML 38 R27.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Short Term Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 54,008	$ 73,970
Unrealized (Loss) Gain	(84)	(187)
Market Value	53,924	73,783
United States Treasury Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	9,857	15,868
Unrealized (Loss) Gain	(7)	(86)
Market Value	9,850	15,782
Commercial Paper and Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	33,328	50,747
Unrealized (Loss) Gain	(53)	(71)
Market Value	33,275	50,676
Asset Backed Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,937	5,427
Unrealized (Loss) Gain	(12)	(35)
Market Value	2,925	5,392
Agency Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	7,886	1,928
Unrealized (Loss) Gain	(12)	5
Market Value	$ 7,874	$ 1,933

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

+ Details

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value Measurements
Assets or liabilities measured at fair value on a non-recurring basis.	$ 0	$ 0

XML 40 R29.htm IDEA: XBRL DOCUMENT

Operating Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases
Cash paid for operating lease liabilities			$ 0.4	$ 0.4
Operating lease rent expense	$ 0.1	$ 0.1	$ 0.4	$ 0.4

XML 41 R30.htm IDEA: XBRL DOCUMENT

Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases
Operating lease obligations (see Note 5 and 6)	$ 788	$ 1,124
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)	$ 424	$ 596
Weighted-average remaining lease term (years)	1 year 7 months 6 days	2 years 3 months 18 days
Weighted-average discount rate	7.20%	7.20%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accrued Liabilities And Other Liabilities [Abstract]
Accrued professional services	$ 313	$ 276
Accrued payroll and employee benefits	2,427	2,955
Accrued research and development	5,537	7,295
Lease obligation, current portion (see Note 4)	485	452
Excess tax refund payable		1,169
Accrued interest and other	63	103
Total accrued expenses and other current liabilities	$ 8,825	$ 12,250

XML 43 R32.htm IDEA: XBRL DOCUMENT

Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Other Long-Term Liabilities
Research and development incentive credit	$ 3,796	$ 3,599
Lease obligation, long-term portion (see Note 4)	303	672
Conditional economic incentive grants	160	250
Other	46	60
Total other long-term liabilities	$ 4,305	$ 4,581

XML 44 R33.htm IDEA: XBRL DOCUMENT

Common Stock - Additional Information (Detail) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended					9 Months Ended		22 Months Ended
	Oct. 18, 2023 shares	Jan. 24, 2022 shares	Feb. 25, 2021 USD ($)	Jul. 16, 2020 $ / shares shares	Feb. 28, 2023 USD ($)	Sep. 30, 2023 USD ($) item $ / shares shares	Jun. 30, 2023 shares	Sep. 30, 2022 shares	Jun. 30, 2022 shares	Mar. 31, 2022 shares	Sep. 30, 2023 USD ($) item $ / shares shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares
Changes In Equity And Comprehensive Income Line Items [Line Items]
Proceeds from issuance of common stock in public offering \| $											$ 13,862	$ 56,166
Common stock, shares authorized						200,000,000					200,000,000		200,000,000
Common stock, par or stated value per share \| $ / shares						$ 0.0001					$ 0.0001		$ 0.0001
Common stock, shares issued						52,858,920					52,858,920		49,199,845
Common stock, shares outstanding						52,858,920					52,858,920		49,199,845
Preferred stock, shares authorized						1,000,000					1,000,000
Preferred stock, par or stated value per share \| $ / shares						$ 0.0001					$ 0.0001
Preferred stock, shares issued						0					0
Preferred stock, shares outstanding						0					0
Warrants outstanding						1,015,166					1,015,166
Exercise price of warrants or rights \| $ / shares						$ 0.66					$ 0.66
Weighted average remaining contractual term, warrants											2 months 12 days
Pre-Funded Warrants [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Number of securities called by warrants or rights		760,870
Shares of common stock sold		760,870
Warrants outstanding						869,566					869,566
Pre-Funded Warrants [Member] \| Subsequent Event
Changes In Equity And Comprehensive Income Line Items [Line Items]
Number of securities called by warrants or rights	869,566
Shares of common stock sold	869,530
Warrants outstanding	0
Common Stock [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Voting right \| item						1					1
Shares of common stock sold						171,653	3,364,631	2,711,013	2,157,717	335,485
Public Offering [Member] \| Pre-Funded Warrants [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Purchase price of warrants issued \| $ / shares				$ 22.9999
Ownership percentage on exercise of warrants without notice, minimum				4.99%
Ownership percentage on exercise of warrants with notice, maximum				19.99%
Notice period to increase ownership percentage on exercise of warrants				61 days
Number of securities called by warrants or rights				1,630,436
Exercise price of warrants or rights \| $ / shares				$ 0.0001
Public Offering [Member] \| Common Stock [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Public offering price, per share \| $ / shares				$ 23.00
Shares of common stock sold				3,369,564
At-The-Market Offering [Member] \| Equity Distribution Agreement [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Remaining shares available for issuance						0					0
At-The-Market Offering [Member] \| Equity Distribution Agreement [Member] \| Evercore Group and JMP Securities LLC and B Riley Securities [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Common stock available to be sold \| $						$ 135,700					$ 135,700
Deferred Offering Costs \| $					$ 200	$ 200					200
Proceeds from issuance of common stock in public offering \| $											$ 13,900
Aggregate offering price \| $					$ 150,000
Shares of common stock sold											3,536,284
Issuance costs \| $											$ 400
At-The-Market Offering [Member] \| Equity Distribution Agreement [Member] \| Piper Sandler company and Evercore group limited liability company and B Riley Securities inc [Member]
Changes In Equity And Comprehensive Income Line Items [Line Items]
Proceeds from issuance of common stock in public offering \| $													$ 121,000
Aggregate offering price \| $			$ 125,000
Shares of common stock sold													10,004,869
Issuance costs \| $													$ 4,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employees purchased, value	$ 80		$ 135	$ 68		$ 113
Stock-based compensation expense							$ 8,171	$ 6,209
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Stock Options, Granted							1,760,026
Stock options granted, weighted-average exercise price							$ 9.71
Stock option expiration Period							10 years
Weighted-average grant date fair value of stock options granted							$ 7.86
Unrecognized compensation cost, stock options	$ 17,900						$ 17,900
Unrecognized stock-based compensation expense, period for recognition							2 years 8 months 12 days
Restricted stock vesting period							4 years
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, period for recognition							2 years 8 months 12 days
Restricted stock authorized and granted							319,700
Weighted average grant date fair value of restricted stock award							$ 13.20
Unrestricted common stock							61,928
Number of shares vested							100,642
Common stock withheld to satisfy tax withholding obligations.							38,714
Unvested restricted stock, shares	618,543						618,543
Unrecognized compensation expense	$ 5,100						$ 5,100
Restricted stock vesting period							4 years
Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrestricted common stock	1,261	6,320	54,347	(7,744)	(5,865)	17,568
Employees purchased, shares	28,345		13,215	9,945		16,450
2019 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employees purchased, shares							41,560
Employees purchased, value							$ 200
Stock-based compensation expense							$ 100	$ 200

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Stock-Based Compensation
Number of Stock Options, Outstanding \| shares	5,079,329
Number of Stock Options, Exercisable \| shares	2,260,984
Number of Stock Options, Vested and expected to vest \| shares	4,769,311
Weighted-average Exercise Price, Outstanding \| $ / shares	$ 9.31
Weighted-average Exercise Price, Exercisable \| $ / shares	8.81
Weighted-average Exercise Price, Vested and expected to vest \| $ / shares	$ 9.28
Weighted-average Remaining Contractual Term, Outstanding	5 years 10 months 24 days
Weighted-average Remaining Contractual Term, Exercisable	5 years 9 months 18 days
Weighted-average Remaining Contractual Term, Vested and expected to vest	5 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding \| $	$ 239
Aggregate Intrinsic Value, Exercisable \| $	200
Aggregate Intrinsic Value, Vested and expected to vest \| $	$ 235

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock based compensation expense	$ 2,710	$ 2,128	$ 8,171	$ 6,209
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock based compensation expense	1,164	743	3,560	2,024
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock based compensation expense	$ 1,546	$ 1,385	$ 4,611	$ 4,185

XML 48 R37.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	145,600	145,600
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	5,144,429	3,542,534
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	618,543	470,275
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		13,454

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details) - Spitfire Pharma, Inc. [Member] - Sales Milestones [Member] $ in Millions	Jul. 12, 2019 USD ($)
Commitments And Contingencies [Line Items]
Estimated future contingent consideration	$ 80.0
License agreement term	10 years

XML 50 R39.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - $ / shares			1 Months Ended
Subsequent Events (Details) - $ / shares	Oct. 18, 2023	Jan. 24, 2022	Oct. 31, 2023	Sep. 30, 2023
Subsequent Event [Line Items]
Exercise price of warrants or rights				$ 0.66
Warrants outstanding				1,015,166
Pre-Funded Warrants
Subsequent Event [Line Items]
Shares of common stock sold		760,870
Warrants outstanding				869,566
Number of securities called by warrants or rights		760,870
Subsequent Event [Member] \| Pre-Funded Warrants
Subsequent Event [Line Items]
Shares of common stock sold	869,530
Warrants outstanding	0
Number of securities called by warrants or rights	869,566
Subsequent Event [Member] \| Other Warrants
Subsequent Event [Line Items]
Exercise price of warrants or rights			$ 5.31
Number of warrants expired unexercised			95,600
Subsequent Event [Member] \| Warrants Maturing on March 12, 2024
Subsequent Event [Line Items]
Exercise price of warrants or rights			$ 3.21
Warrants outstanding			50,000

XML 51 alt-20230930x10q_htm.xml IDEA: XBRL DOCUMENT 0001326190 alt:PreFundedWarrantsMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0001326190 alt:PreFundedWarrantsMember 2022-01-24 2022-01-24 0001326190 us-gaap:CommonStockMember us-gaap:IPOMember 2020-07-16 2020-07-16 0001326190 us-gaap:RetainedEarningsMember 2023-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001326190 us-gaap:RetainedEarningsMember 2023-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001326190 2023-06-30 0001326190 us-gaap:RetainedEarningsMember 2023-03-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001326190 2023-03-31 0001326190 us-gaap:RetainedEarningsMember 2022-12-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001326190 us-gaap:RetainedEarningsMember 2022-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001326190 us-gaap:RetainedEarningsMember 2022-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001326190 2022-06-30 0001326190 us-gaap:RetainedEarningsMember 2022-03-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001326190 2022-03-31 0001326190 us-gaap:RetainedEarningsMember 2021-12-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001326190 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001326190 us-gaap:CommonStockMember 2023-06-30 0001326190 us-gaap:CommonStockMember 2023-03-31 0001326190 us-gaap:CommonStockMember 2022-12-31 0001326190 us-gaap:CommonStockMember 2022-09-30 0001326190 us-gaap:CommonStockMember 2022-06-30 0001326190 us-gaap:CommonStockMember 2022-03-31 0001326190 us-gaap:CommonStockMember 2021-12-31 0001326190 us-gaap:CommonStockMember us-gaap:IPOMember 2020-07-16 0001326190 alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001326190 alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2022-01-01 2022-09-30 0001326190 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001326190 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001326190 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001326190 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001326190 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001326190 alt:EvercoreGroupAndJmpSecuritiesLlcAndBRileySecuritiesMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2023-01-01 2023-09-30 0001326190 alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2021-02-25 2022-12-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001326190 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001326190 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001326190 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001326190 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001326190 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001326190 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001326190 us-gaap:EmployeeStockOptionMember 2023-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001326190 alt:EvercoreGroupAndJmpSecuritiesLlcAndBRileySecuritiesMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2023-02-28 0001326190 alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2023-09-30 0001326190 alt:PreFundedWarrantsMember 2023-09-30 0001326190 alt:PreFundedWarrantsMember us-gaap:SubsequentEventMember 2023-10-18 0001326190 alt:PreFundedWarrantsMember 2022-01-24 0001326190 alt:WarrantsMaturingOnMarch122024Member us-gaap:SubsequentEventMember 2023-10-31 0001326190 alt:OtherWarrantsMember us-gaap:SubsequentEventMember 2023-10-31 0001326190 alt:PreFundedWarrantsMember us-gaap:IPOMember 2020-07-16 0001326190 2022-09-30 0001326190 2021-12-31 0001326190 alt:SpitfirePharmaIncMember alt:SalesMilestoneMember 2019-07-12 0001326190 us-gaap:USTreasurySecuritiesMember 2023-09-30 0001326190 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001326190 us-gaap:AssetBackedSecuritiesMember 2023-09-30 0001326190 alt:CommercialPaperAndCorporateDebtSecuritiesMember 2023-09-30 0001326190 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001326190 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001326190 us-gaap:AssetBackedSecuritiesMember 2022-12-31 0001326190 alt:CommercialPaperAndCorporateDebtSecuritiesMember 2022-12-31 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001326190 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001326190 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001326190 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001326190 2023-07-01 2023-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001326190 2023-04-01 2023-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001326190 2023-01-01 2023-03-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001326190 2022-07-01 2022-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001326190 2022-04-01 2022-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001326190 2022-01-01 2022-03-31 0001326190 2023-11-03 0001326190 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001326190 2022-01-01 2022-09-30 0001326190 us-gaap:CommonStockMember 2023-09-30 0001326190 alt:EvercoreGroupAndJmpSecuritiesLlcAndBRileySecuritiesMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2023-09-30 0001326190 2023-01-01 2023-09-30 0001326190 alt:PreFundedWarrantsMember us-gaap:IPOMember 2020-07-16 2020-07-16 0001326190 alt:OtherWarrantsMember us-gaap:SubsequentEventMember 2023-10-01 2023-10-31 0001326190 alt:SpitfirePharmaIncMember alt:SalesMilestoneMember 2019-07-12 2019-07-12 0001326190 alt:EvercoreGroupAndJmpSecuritiesLlcAndBRileySecuritiesMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2023-02-01 2023-02-28 0001326190 alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2021-02-25 2021-02-25 0001326190 2023-09-30 0001326190 2022-12-31 iso4217:USD shares iso4217:USD shares alt:item pure

-0.39

-0.48

-1.10

-1.37

53633354

49286535

51495957

45881547

52858920

49199845

false 0001326190 --12-31 2023 Q3

52858920

10-Q true 2023-09-30 false 001-32587 ALTIMMUNE, INC. DE 20-2726770 910 Clopper Road Suite 201S Gaithersburg MD 20878 240 654-1450 Common stock, par value $0.0001 per share ALT NASDAQ Yes Yes Non-accelerated Filer true false false 53728871

86855000

111097000

41000

34000

86896000

111131000

53924000

73783000

876000

173000

3653000 2368000

7615000

5358000

152964000

192813000

765000

1081000

12419000

425000

615000

166573000

206928000

3046000

4804000

8825000 12250000

11871000

17054000

4305000

4581000

16176000

21635000

0.0001

200000000

52858920

49199845

5000

590206000

568399000

-434690000

-377884000

-5124000

-5227000

150397000

185293000

166573000

206928000

362000

2000

389000

42000

18388000

20262000

48890000

51359000

4514000

4492000

13805000

13329000

22902000

24754000

62695000

64688000

-22540000

-24752000

-62306000

-64646000

29000

64000

33000

191000

1884000

1053000

5387000

1402000

14000

50000

146000

185000

1869000

1039000

5500000

1396000

-20671000

-23713000

-56806000

-63250000

-197000

-20671000

-23516000

-56806000

-63053000

56000

-143000

103000

-263000

-20615000

-23659000

-56703000

-63316000

-0.39

-0.48

-1.10

-1.37

53633354

49286535

51495957

45881547

49199845

5000

568399000

-377884000

-5227000

185293000

2675000

19303

61000

54347

-484000

13215

135000

126000

-20074000

49286710

5000

570786000

-397958000

-5101000

167732000

2786000

6320

-16000

3364631

13352000

-79000

-16061000

52657661

5000

586908000

-414019000

-5180000

167714000

2710000

1261

-2000

171653

510000

28345

80000

56000

-20671000

52858920

5000

590206000

-434690000

-5124000

150397000

40993768

4000

497342000

-293171000

-5040000

199135000

2033000

95771

197000

17568

-170000

16450

113000

335485

2990000

1760854

-19430000

43219896

4000

502505000

-312601000

-5040000

184868000

2048000

152913

403000

-5865

-80000

2157717

1000

21346000

21347000

847444

6176000

-120000

-20107000

46372105

5000

532398000

-332708000

-5160000

194535000

2128000

76161

268000

-7744

-140000

2711013

31829000

9945

68000

157

-143000

-23516000

49161637

5000

566551000

-356224000

-5303000

205029000

-56806000

-63053000

86000

8171000

6209000

-1413000

31000

134000

183000

704000

204000

2043000

-3204000

-1758000

-615000

-3306000

7555000

1284000 -1690000

-59277000

-45280000

76544000

54806000

74292000

47000

88000

21691000

-74380000

195000

13862000

56166000

215000

181000

90000

61000

868000

502000

391000

13351000

56824000

-24235000

-62836000

111131000

190335000

86896000

127499000

6176000

1. Nature of Business and Basis of PresentationNature of BusinessAltimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (“HepTcellTM”). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.Basis of PresentationThe accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022 included in the Annual Report on Form 10-K which was filed with the SEC on February 28, 2023. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2023 or any future years or periods.The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accounting PoliciesDuring the nine months ended September 30, 2023, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC, except for the recently adopted accounting standard for ASU No. 2016-13 as disclosed below.Use of EstimatesThe preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.Short-term InvestmentsThe Company’s short-term investments are comprised of U.S. Treasuries, corporate debt securities and certificates of deposit that have original maturities less than or equal to one year and are classified as available-for-sale (“AFS”) securities. Such securities are carried at estimated fair value, net of allowance for credit loss determined based on the Current Expected Credit Loss. Any unrealized holding gains or losses are reported as accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. In the event that the AFS security's fair value is below the amortized cost and (i) the Company intends to sell the AFS security and (ii) the AFS security is required to be sold before recovery of the loss, the AFS security's amortized cost base will be written down to its fair value and the loss will be recognized in the income statement. If the Company intends not to sell the AFS security and the AFS security is not required to be sold before recovery of the loss, the Company evaluates whether a portion of the unrealized loss is a result of credit loss. The portion of unrealized loss related to credit loss will be recorded as allowance for credit loss in the balance sheet with the corresponding credit loss in the income statement and the portion of unrealized loss not related to credit loss will be recognized in other comprehensive income (“OCI”). Dividend and interest income are recognized in other income when earned. The cost of securities sold is calculated using the specific identification method. The Company places all investments with government agencies, or corporate institutions whose debt is rated as investment grade. As of September 30, 2023, none of the unrealized losses on the Company’s short-term investments are a result of credit loss, and therefore, the unrealized losses were recognized in OCI.Income TaxesDuring the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax expense (benefit) for either of the three and nine months ended September 30, 2023 or 2022 due to a full valuation allowance. The Company calculates its quarterly income tax provision based on an estimated, annual effective tax rate applied to ordinary income (or loss) and other known items computed and recognized as they occur. The Company’s total provision is based on the United States statutory rate, increased by state and foreign taxes and reduced by a full valuation allowance on the Company’s deferred tax assets.Recently adopted accounting pronouncementsIn June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”). ASU No. 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and any unrealized loss relating to available-for-sale debt securities to be recorded through an allowance for credit losses. The Company adopted this new accounting standard on January 1, 2023 using a modified retrospective method. Adoption of this update did not have a material impact on the Company’s financial statements and related disclosures.

Use of EstimatesThe preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, income taxes, and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.

Short-term InvestmentsThe Company’s short-term investments are comprised of U.S. Treasuries, corporate debt securities and certificates of deposit that have original maturities less than or equal to one year and are classified as available-for-sale (“AFS”) securities. Such securities are carried at estimated fair value, net of allowance for credit loss determined based on the Current Expected Credit Loss. Any unrealized holding gains or losses are reported as accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. In the event that the AFS security's fair value is below the amortized cost and (i) the Company intends to sell the AFS security and (ii) the AFS security is required to be sold before recovery of the loss, the AFS security's amortized cost base will be written down to its fair value and the loss will be recognized in the income statement. If the Company intends not to sell the AFS security and the AFS security is not required to be sold before recovery of the loss, the Company evaluates whether a portion of the unrealized loss is a result of credit loss. The portion of unrealized loss related to credit loss will be recorded as allowance for credit loss in the balance sheet with the corresponding credit loss in the income statement and the portion of unrealized loss not related to credit loss will be recognized in other comprehensive income (“OCI”). Dividend and interest income are recognized in other income when earned. The cost of securities sold is calculated using the specific identification method. The Company places all investments with government agencies, or corporate institutions whose debt is rated as investment grade. As of September 30, 2023, none of the unrealized losses on the Company’s short-term investments are a result of credit loss, and therefore, the unrealized losses were recognized in OCI.

Income TaxesDuring the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax expense (benefit) for either of the three and nine months ended September 30, 2023 or 2022 due to a full valuation allowance. The Company calculates its quarterly income tax provision based on an estimated, annual effective tax rate applied to ordinary income (or loss) and other known items computed and recognized as they occur. The Company’s total provision is based on the United States statutory rate, increased by state and foreign taxes and reduced by a full valuation allowance on the Company’s deferred tax assets.

-200000

Recently adopted accounting pronouncementsIn June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”). ASU No. 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected and any unrealized loss relating to available-for-sale debt securities to be recorded through an allowance for credit losses. The Company adopted this new accounting standard on January 1, 2023 using a modified retrospective method. Adoption of this update did not have a material impact on the Company’s financial statements and related disclosures.

3. Fair Value MeasurementsThe Company’s assets measured at fair value on a recurring basis as of September 30, 2023 consisted of the following (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value Measurement at September 30, 2023</td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;">Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;">Cash equivalents - money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 82,102</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 82,102</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;">Short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 53,924</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 53,924</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 136,026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 82,102</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,924</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>The Company’s assets measured at fair value on a recurring basis as of December 31, 2022 consisted of the following (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value Measurement at December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;">Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;">Cash equivalents - money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 105,794</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 105,794</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;">Short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 73,783</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 73,783</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 179,577</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 105,794</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,783</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table> Short-term investments have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third party pricing services or other market observable data (Level 2). The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value.Short-term investments with quoted prices as of September 30, 2023 as shown below (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amortized Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Unrealized (Loss) Gain</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Credit loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Market Value</td></tr><tr><td style="vertical-align:bottom;width:46.77%;background:#cceeff;margin:0pt;padding:0pt;">United States treasury securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 9,857</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (7)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 9,850</td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;">Commercial paper and corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 33,328</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"> (53)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> 33,275</td></tr><tr><td style="vertical-align:bottom;width:46.77%;background:#cceeff;margin:0pt;padding:0pt;">Asset backed securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (12)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2,925</td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;">Agency debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,886</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,874</td></tr><tr><td style="vertical-align:bottom;width:46.77%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 54,008</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (84)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,924</td></tr></table>Short-term investments with quoted prices as of December 31, 2022 as shown below (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amortized Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Unrealized (Loss) Gain</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Credit Loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Market Value</td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;">United States treasury securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 15,868</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (86)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 15,782</td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;">Commercial paper and corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 50,747</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"> (71)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> 50,676</td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;">Asset backed securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 5,427</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (35)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5,392</td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;">Agency debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,928</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,933</td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,970</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (187)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,783</td></tr></table>Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the nine months ended September 30, 2023 and year ended December 31, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis.

The Company’s assets measured at fair value on a recurring basis as of September 30, 2023 consisted of the following (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value Measurement at September 30, 2023</td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;">Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;">Cash equivalents - money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 82,102</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 82,102</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;">Short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 53,924</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 53,924</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 136,026</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 82,102</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,924</td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>The Company’s assets measured at fair value on a recurring basis as of December 31, 2022 consisted of the following (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value Measurement at December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;">Assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;">Cash equivalents - money market funds</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 105,794</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> 105,794</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;">Short-term investments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 73,783</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 73,783</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 179,577</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 105,794</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,783</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr></table>

82102000

53924000

136026000

82102000

53924000

105794000

73783000

179577000

105794000

73783000

Short-term investments with quoted prices as of September 30, 2023 as shown below (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amortized Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Unrealized (Loss) Gain</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Credit loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Market Value</td></tr><tr><td style="vertical-align:bottom;width:46.77%;background:#cceeff;margin:0pt;padding:0pt;">United States treasury securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 9,857</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (7)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 9,850</td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;">Commercial paper and corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 33,328</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"> (53)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> 33,275</td></tr><tr><td style="vertical-align:bottom;width:46.77%;background:#cceeff;margin:0pt;padding:0pt;">Asset backed securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (12)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2,925</td></tr><tr><td style="vertical-align:bottom;width:46.77%;margin:0pt;padding:0pt;">Agency debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,886</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,874</td></tr><tr><td style="vertical-align:bottom;width:46.77%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 54,008</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (84)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53,924</td></tr></table>Short-term investments with quoted prices as of December 31, 2022 as shown below (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Amortized Cost</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Unrealized (Loss) Gain</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Credit Loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Market Value</td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;">United States treasury securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 15,868</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (86)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 15,782</td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;">Commercial paper and corporate debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 50,747</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"> (71)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"> 50,676</td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;">Asset backed securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 5,427</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"> (35)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5,392</td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;">Agency debt securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,928</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,933</td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,970</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (187)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 73,783</td></tr></table>

9857000

-7000

9850000

33328000

-53000

33275000

2937000

-12000

2925000

7886000

-12000

7874000

54008000

-84000

53924000

15868000

-86000

15782000

50747000

-71000

50676000

5427000

-35000

5392000

1928000

5000

1933000

73970000

-187000

73783000

0 0

4. Operating LeasesThe Company’s operating leases consist of leases for office and laboratory space in the United States, which expire in April 2025. Rent expense under the Company’s operating leases was $0.1 million and $0.4 million during the three and nine months ended September 30, 2023. During the three and nine months ended September 30, 2022, rent expense under the Company’s operating leases was $0.1 million and $0.4 million, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation.Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreements. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised.The cash paid for operating lease liabilities for each of the nine months ended September 30, 2023 and 2022 was $0.4 million.Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;">Operating lease obligations (see Note 5 and 6)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"> 788</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,124</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;">Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> 424</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> 596</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;">Weighted-average remaining lease term (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"> 1.6</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 2.3</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;">Weighted-average discount rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> 7.2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> 7.2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">%</td></tr></table>

100000

400000

100000

400000

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;">Operating lease obligations (see Note 5 and 6)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"> 788</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,124</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;">Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> 424</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> 596</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;">Weighted-average remaining lease term (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"> 1.6</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 2.3</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;">Weighted-average discount rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"> 7.2</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> 7.2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;">%</td></tr></table>

788000

1124000

424000

596000

P1Y7M6D

P2Y3M18D

0.072

5. Accrued ExpensesAccrued expenses and other current liabilities consist of the following (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Accrued professional services</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"> 313</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"> 276</td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;">Accrued payroll and employee benefits</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"> 2,427</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 2,955</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Accrued research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"> 5,537</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"> 7,295</td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;">Lease obligation, current portion (see Note 4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"> 485</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 452</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Excess tax refund payable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"> 1,169</td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;">Accrued interest and other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 63</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 103</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Total accrued expenses and other current liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,825</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,250</td></tr></table>

Accrued expenses and other current liabilities consist of the following (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Accrued professional services</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"> 313</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"> 276</td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;">Accrued payroll and employee benefits</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"> 2,427</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 2,955</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Accrued research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"> 5,537</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"> 7,295</td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;">Lease obligation, current portion (see Note 4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"> 485</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> 452</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Excess tax refund payable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"> 1,169</td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;">Accrued interest and other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 63</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 103</td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;">Total accrued expenses and other current liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,825</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,250</td></tr></table>

313000

276000

2427000

2955000

5537000 7295000

485000

452000

1169000

63000

103000

8825000 12250000

6. Other Long-Term LiabilitiesThe Company’s other long-term liabilities are summarized as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;">Research and development incentive credit</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 3,796</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 3,599</td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;">Lease obligation, long-term portion (see Note 4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"> 303</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"> 672</td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;">Conditional economic incentive grants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 160</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 250</td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 60</td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;">Total other long-term liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,305</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,581</td></tr></table>

The Company’s other long-term liabilities are summarized as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, 2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;">Research and development incentive credit</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 3,796</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 3,599</td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;">Lease obligation, long-term portion (see Note 4)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"> 303</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"> 672</td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;">Conditional economic incentive grants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 160</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"> 250</td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 60</td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;">Total other long-term liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,305</td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,581</td></tr></table>

3796000 3599000

303000

672000

160000 250000

46000

60000

4305000

4581000

7. Common StockThe Amended and Restated Certificate of Incorporation, as amended (“Charter”), authorizes the Company to issue 200,000,000 shares of common stock, par value $0.0001 per share. As of September 30, 2023, the Company had 52,858,920 shares of common stock issued and outstanding.Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.The Charter also authorizes the Company to issue 1,000,000 shares of preferred stock, par value $0.0001 per share. As of September 30, 2023, the Company had no shares of preferred stock issued and outstanding.At-the-Market OfferingsOn February 28, 2023, the Company entered into an Equity Distribution Agreement (the “2023 Agreement”) with Evercore Group L.L.C., JMP Securities LLC and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”), with respect to an at-the-market offerings program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $150.0 million (the “Shares”) through the Sales Agents (the “2023 Offering”). All Shares offered and sold in the 2023 Offering will be issued pursuant to the Company’s Registration Statement on Form S-3ASR filed with the SEC on February 28, 2023, which was declared effective immediately, the prospectus supplement relating to the 2023 Offering filed with the SEC on February 28, 2023 and any applicable additional prospectus supplements related to the 2023 Offering that form a part of the Registration Statement. The Company capitalized approximately $0.2 million of other offering costs which will offset the proceeds received from the shares sold under the 2023 Agreement. During the nine months ended September 30, 2023, the Company sold 3,536,284 shares of common stock under the 2023 Agreement resulting in approximately $13.9 million in proceeds, net of $0.4 million commission and other offering costs. As of September 30, 2023, $135.7 million remained available to be sold under the 2023 Agreement. As of September 30, 2023, there was $0.2 million in deferred offering costs included in prepaid expenses and other current assets on the accompanying consolidated balance sheets.On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “2021 Sales Agents”), with respect to an at-the-market offerings program under which the Company offered and sold shares of its common stock, having an aggregate offering price of up to $125.0 million (the “2021 Shares”) through the 2021 Sales Agents (the “2021 Offering”). All 2021 Shares offered and sold in the 2021 Offering were issued pursuant to the Company’s Registration Statement on Form S-3 filed with the SEC on December 31, 2020, which was declared effective on January 11, 2021, the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement. Under the 2021 Agreement, the Company sold 10,004,869 shares of common stock resulting in approximately $121.0 million in proceeds, net of $4.0 million commission and other offering costs. As of September 30, 2023, there were no remaining shares available under the 2021 Agreement.Public OfferingOn July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of common stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company.The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, Derivatives and Hedging (“ASC 815”). The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the Pre-Funded Warrants were classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. On January 24, 2022, 760,870 of the Pre-Funded Warrants were exercised, resulting in the issuance of 760,870 shares of common stock. As of September 30, 2023, there were 869,566 remaining Pre-Funded Warrants unexercised. Subsequent to September 30, 2023, the remaining Pre-Funded Warrants were net cashless exercised, and currently no Pre-Funded Warrants remain available for exercise (see Note 11 Subsequent Events).As of September 30, 2023, including the remaining 869,566 Pre-Funded Warrants, there were 1,015,166 outstanding warrants with a weighted-average exercise price of $0.66 and weighted-average contractual term of 0.2 years.

200000000

0.0001

52858920

1000000

0.0001

150000000.0

200000

3536284

13900000

400000

135700000

200000

125000000.0

10004869

121000000.0

4000000.0

3369564

23.00

1630436

0.0001

22.9999 0.0499 0.1999 P61D

760870

869566

1015166

0.66

P0Y2M12D

8. Stock-Based CompensationStock OptionsThe Company’s stock option awards generally vest over four years and typically have a contractual life of ten years. As of September 30, 2023, there was $17.9 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 2.7 years. During the nine months ended September 30, 2023, the Company granted 1,760,026 stock options with a weighted average exercise price of $9.71 and per share weighted average grant date fair value of $7.86.Information related to stock options outstanding as of September 30, 2023 is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;">Weighted-Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;">Contractual Term</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;">Aggregate Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Stock Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercise Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value (In thousands)</td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,079,329</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.9</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 239</td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;">Exercisable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,260,984</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8.81</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.8</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 200</td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;">Vested and expected to vest</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,769,311</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9.28</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.9</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 235</td></tr></table>Restricted Stock Units (RSUs)During the nine months ended September 30, 2023, the Company granted 319,700 shares of RSUs with a weighted average grant date fair value of $13.20 which vest over four years. As of September 30, 2023, the Company had unvested RSUs of 618,543 shares with total unrecognized compensation expense of $5.1 million, which the Company expects to recognize over a weighted average period of approximately 2.7 years. During the nine months ended September 30, 2023, the Company issued 61,928 shares of unrestricted common stock as a result of the vesting of 100,642 RSUs net of 38,714 shares of common stock withheld to satisfy tax withholding obligations.2019 Employee Stock Purchase Plan (ESPP)Under the ESPP, employees purchased 41,560 shares for $0.2 million during the nine months ended September 30, 2023. During the nine months ended September 30, 2023 and 2022, the Company recognized compensation expense of $0.1 million and $0.2 million, respectively.Stock-based Compensation ExpenseStock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2022 as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.45%;margin:0pt;padding:0pt;">Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1,164</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 743</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 3,560</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> 2,024</td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,546</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,385</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,611</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,185</td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,710</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,128</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,171</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,209</td></tr></table>

P4Y

P10Y

17900000

P2Y8M12D

1760026

9.71

7.86

Information related to stock options outstanding as of September 30, 2023 is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;">Weighted-Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;">Contractual Term</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;">Aggregate Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Stock Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercise Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value (In thousands)</td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,079,329</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.9</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 239</td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;">Exercisable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,260,984</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8.81</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.8</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 200</td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;">Vested and expected to vest</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,769,311</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9.28</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.9</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 235</td></tr></table>

5079329

9.31

P5Y10M24D

239000

2260984

8.81

P5Y9M18D

200000

4769311

9.28

P5Y10M24D

235000

319700

13.20

P4Y

618543

5100000

P2Y8M12D

61928

100642

38714

41560

200000

100000

200000

Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023 and 2022 as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.45%;margin:0pt;padding:0pt;">Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1,164</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 743</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"> 3,560</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"> 2,024</td></tr><tr><td style="vertical-align:bottom;width:55.55%;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,546</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,385</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,611</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,185</td></tr><tr><td style="vertical-align:bottom;width:55.55%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,710</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,128</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,171</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,209</td></tr></table>

1164000

743000

3560000

2024000

1546000

1385000

4611000

4185000

2710000

2128000

8171000

6209000

9. Net Loss Per ShareBecause the Company has reported a net loss attributable to common stockholders for the nine months ended September 30, 2023 and 2022, basic and diluted net loss per share attributable to common stockholders in each period are the same.Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock.Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, RSUs, common stock warrants, and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, RSUs, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.38%;margin:0pt;padding:0pt;">Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;">Common stock warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"> 145,600</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 145,600</td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;">Common stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> 5,144,429</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 3,542,534</td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;">Restricted stock units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"> 618,543</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 470,275</td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;">Restricted stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 13,454</td></tr></table>

Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, RSUs, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.38%;margin:0pt;padding:0pt;">Nine Months Ended </td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">September 30, </td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;">Common stock warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"> 145,600</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 145,600</td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;">Common stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> 5,144,429</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 3,542,534</td></tr><tr><td style="vertical-align:bottom;width:74.25%;background:#cceeff;margin:0pt;padding:0pt;">Restricted stock units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"> 618,543</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"> 470,275</td></tr><tr><td style="vertical-align:bottom;width:74.25%;margin:0pt;padding:0pt;">Restricted stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"> 13,454</td></tr></table>

145600

5144429

3542534

618543

470275

13454

10. Commitments and ContingenciesSpitfire AcquisitionIn July 2019, the Company entered into the Spitfire merger agreement to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”). As part of the agreement, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. (the “Sales Milestone”) within ten years following the approval of a new drug application filed with the U. S. Food and Drug Administration (the “FDA”).The contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, Contingencies. Accordingly, the Company will recognize the Sales Milestones when the contingency is probable and the amount can be reasonably estimated.LitigationThe Company is a party in various contracts and subject to disputes, litigation, and potential claims arising in the ordinary course of business none of which are currently reasonably possible or probable of material loss.

80000000.0

P10Y

11. Subsequent EventsOn October 18, 2023, warrant holders exercised the remaining 869,566 Pre-Funded Warrants in a net cashless exercise and were issued 869,530 shares of common stock in a net cashless exercise (see Note 7 Common Stock).In addition, in October 2023, 95,600 various other warrants with a weighted-average exercise price of $5.31 expired unexercised. The only remaining outstanding 50,000 warrants have an exercise price of $3.21 and have a maturity date of March 12, 2024.

869566

869530

95600

5.31

50000

3.21

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " #]@&=7_WEJDI\! =& $P @ '#W0 I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 +P O , , "3WP ! end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 133 209 1 false 32 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.altimmune.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.altimmune.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Nature of Business and Organization Sheet http://www.altimmune.com/role/DisclosureNatureOfBusinessAndOrganization Nature of Business and Organization Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Fair Value Measurements Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 10401 - Disclosure - Operating Leases Sheet http://www.altimmune.com/role/DisclosureOperatingLeases Operating Leases Notes 10 false false R11.htm 10501 - Disclosure - Accrued Expenses Sheet http://www.altimmune.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 10601 - Disclosure - Other Long-Term Liabilities Sheet http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities Other Long-Term Liabilities Notes 12 false false R13.htm 10701 - Disclosure - Common Stock Sheet http://www.altimmune.com/role/DisclosureCommonStock Common Stock Notes 13 false false R14.htm 10801 - Disclosure - Stock-Based Compensation Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 10901 - Disclosure - Net Loss Per Share Sheet http://www.altimmune.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 11001 - Disclosure - Commitments and Contingencies Sheet http://www.altimmune.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 11101 - Disclosure - Subsequent Events Sheet http://www.altimmune.com/role/DisclosureSubsequentEvents Subsequent Events Notes 17 false false R18.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.altimmune.com/role/DisclosureFairValueMeasurements 19 false false R20.htm 30403 - Disclosure - Operating Leases (Tables) Sheet http://www.altimmune.com/role/DisclosureOperatingLeasesTables Operating Leases (Tables) Tables http://www.altimmune.com/role/DisclosureOperatingLeases 20 false false R21.htm 30503 - Disclosure - Accrued Expenses (Tables) Sheet http://www.altimmune.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.altimmune.com/role/DisclosureAccruedExpenses 21 false false R22.htm 30603 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities 22 false false R23.htm 30803 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.altimmune.com/role/DisclosureStockBasedCompensation 23 false false R24.htm 30903 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.altimmune.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.altimmune.com/role/DisclosureNetLossPerShare 24 false false R25.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 25 false false R26.htm 40301 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) Details 26 false false R27.htm 40302 - Disclosure - Fair Value Measurements - Schedule of Short Term Investments (Detail) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail Fair Value Measurements - Schedule of Short Term Investments (Detail) Details 27 false false R28.htm 40303 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 28 false false R29.htm 40401 - Disclosure - Operating Leases - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail Operating Leases - Additional Information (Detail) Details 29 false false R30.htm 40402 - Disclosure - Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) Sheet http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) Details 30 false false R31.htm 40501 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Details 31 false false R32.htm 40601 - Disclosure - Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) Sheet http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) Details 32 false false R33.htm 40701 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail Common Stock - Additional Information (Detail) Details 33 false false R34.htm 40801 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 34 false false R35.htm 40802 - Disclosure - Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) Details 35 false false R36.htm 40803 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) Details 36 false false R37.htm 40901 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Sheet http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Details 37 false false R38.htm 41001 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 38 false false R39.htm 41101 - Disclosure - Subsequent Events (Details) Sheet http://www.altimmune.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.altimmune.com/role/DisclosureSubsequentEvents 39 false false All Reports Book All Reports alt-20230930.xsd alt-20230930_cal.xml alt-20230930_def.xml alt-20230930_lab.xml alt-20230930_pre.xml alt-20230930x10q.htm alt-20230930x10q002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "alt-20230930x10q.htm": { "nsprefix": "alt", "nsuri": "http://www.altimmune.com/20230930", "dts": { "schema": { "local": [ "alt-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "alt-20230930_cal.xml" ] }, "definitionLink": { "local": [ "alt-20230930_def.xml" ] }, "labelLink": { "local": [ "alt-20230930_lab.xml" ] }, "presentationLink": { "local": [ "alt-20230930_pre.xml" ] }, "inline": { "local": [ "alt-20230930x10q.htm" ] } }, "keyStandard": 186, "keyCustom": 23, "axisStandard": 16, "axisCustom": 0, "memberStandard": 19, "memberCustom": 11, "hidden": { "total": 19, "http://fasb.org/us-gaap/2023": 14, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 133, "entityCount": 1, "segmentCount": 32, "elementCount": 319, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 489, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_Y_IPAg-OQEqSjtmzNpsRqA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_r58RWxOo0Ue2wjHgAIrOag", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_r58RWxOo0Ue2wjHgAIrOag", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sXxps_Ule0G9bSnn0BWFxw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ge6rhGyx70qqO1oG4uhksw", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "unique": true } }, "R6": { "role": "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.altimmune.com/role/DisclosureNatureOfBusinessAndOrganization", "longName": "10101 - Disclosure - Nature of Business and Organization", "shortName": "Nature of Business and Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurements", "longName": "10301 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.altimmune.com/role/DisclosureOperatingLeases", "longName": "10401 - Disclosure - Operating Leases", "shortName": "Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.altimmune.com/role/DisclosureAccruedExpenses", "longName": "10501 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities", "longName": "10601 - Disclosure - Other Long-Term Liabilities", "shortName": "Other Long-Term Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.altimmune.com/role/DisclosureCommonStock", "longName": "10701 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "alt:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "alt:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensation", "longName": "10801 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.altimmune.com/role/DisclosureNetLossPerShare", "longName": "10901 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.altimmune.com/role/DisclosureCommitmentsAndContingencies", "longName": "11001 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.altimmune.com/role/DisclosureSubsequentEvents", "longName": "11101 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables", "longName": "30303 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.altimmune.com/role/DisclosureOperatingLeasesTables", "longName": "30403 - Disclosure - Operating Leases (Tables)", "shortName": "Operating Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.altimmune.com/role/DisclosureAccruedExpensesTables", "longName": "30503 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesTables", "longName": "30603 - Disclosure - Other Long-Term Liabilities (Tables)", "shortName": "Other Long-Term Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationTables", "longName": "30803 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.altimmune.com/role/DisclosureNetLossPerShareTables", "longName": "30903 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_9_30_2022_WmZmypQ6Skq7RkxBzbZvZQ", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "longName": "40301 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)", "shortName": "Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:ShortTermInvestments", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_I_L-6ijdp0KObQ3Loc1G5w", "name": "us-gaap:ShortTermInvestments", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "unique": true } }, "R27": { "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail", "longName": "40302 - Disclosure - Fair Value Measurements - Schedule of Short Term Investments (Detail)", "shortName": "Fair Value Measurements - Schedule of Short Term Investments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "longName": "40303 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "alt:AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "alt:AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail", "longName": "40401 - Disclosure - Operating Leases - Additional Information (Detail)", "shortName": "Operating Leases - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:OperatingLeasePayments", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:OperatingLeasePayments", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail", "longName": "40402 - Disclosure - Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail)", "shortName": "Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "longName": "40501 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "shortName": "Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail", "longName": "40601 - Disclosure - Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail)", "shortName": "Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "alt:ResearchAndDevelopmentIncentiveCredit", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "alt:ResearchAndDevelopmentIncentiveCredit", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "longName": "40701 - Disclosure - Common Stock - Additional Information (Detail)", "shortName": "Common Stock - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_GN0nJ9Taxk-tTHGcuG2Qkg", "name": "alt:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "unique": true } }, "R34": { "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "longName": "40801 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_r58RWxOo0Ue2wjHgAIrOag", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oUGcvkvYm0iYO4pfp4Rq8Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_JnPt3BD0o0qloVlh7Nx1gw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "unique": true } }, "R35": { "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail", "longName": "40802 - Disclosure - Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail)", "shortName": "Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_JnPt3BD0o0qloVlh7Nx1gw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_JnPt3BD0o0qloVlh7Nx1gw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "longName": "40803 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)", "shortName": "Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_r58RWxOo0Ue2wjHgAIrOag", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_r58RWxOo0Ue2wjHgAIrOag", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "longName": "40901 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)", "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_zQbahyLWakmH_rp7kBITsQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_JnPt3BD0o0qloVlh7Nx1gw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_zQbahyLWakmH_rp7kBITsQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_JnPt3BD0o0qloVlh7Nx1gw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "41001 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_7_12_2019_us-gaap_BusinessAcquisitionAxis_alt_SpitfirePharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_alt_SalesMilestoneMember_tIcyvpoWikyVWNCBQzMtDw", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_7_12_2019_us-gaap_BusinessAcquisitionAxis_alt_SpitfirePharmaIncMember_us-gaap_ContingentConsiderationByTypeAxis_alt_SalesMilestoneMember_tIcyvpoWikyVWNCBQzMtDw", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_Standard_USD_8wf6wEZVRUGF-dwNzLHT1g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails", "longName": "41101 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2023_v_BVX8vaFECi7U4MAvu1Jw", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_Y_IPAg-OQEqSjtmzNpsRqA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_alt_OtherWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hY4ZNpDfk02o85BU-lvDow", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit_Divide_USD_shares_Y_IPAg-OQEqSjtmzNpsRqA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "alt-20230930x10q.htm", "unique": true } } }, "tag": { "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r354", "r509" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r296", "r297", "r298", "r429", "r546", "r547", "r548", "r593", "r606" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Debt Securities Available For Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock in at the market offerings, net (in shares)", "verboseLabel": "Shares of common stock sold", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r58", "r59", "r84", "r423", "r480", "r485" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment Policy [Text Block]", "terseLabel": "Short-term Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r410", "r418", "r419", "r420", "r421", "r483", "r484" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r51", "r86", "r119", "r121", "r128", "r392", "r408" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r88", "r107", "r137", "r167", "r175", "r179", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r316", "r320", "r339", "r397", "r452", "r510", "r521", "r563", "r564", "r598" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r284" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination Contingent Consideration Liability", "terseLabel": "Estimated future contingent consideration", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r50", "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Number of Stock Options, Vested and expected to vest", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r284" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-average Exercise Price, Vested and expected to vest", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r284" ] }, "us-gaap_OtherLongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Long Term Debt Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r18", "r437" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r22", "r101", "r123", "r124", "r125", "r140", "r141", "r142", "r144", "r150", "r152", "r165", "r218", "r219", "r253", "r296", "r297", "r298", "r308", "r309", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r340", "r341", "r342", "r343", "r344", "r345", "r355", "r412", "r413", "r414", "r429", "r480" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Common stock withheld to satisfy tax withholding obligations.", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r101", "r140", "r141", "r142", "r144", "r150", "r152", "r218", "r219", "r296", "r297", "r298", "r308", "r309", "r322", "r324", "r325", "r327", "r329", "r412", "r414", "r429", "r606" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain Loss Unrealized", "negatedLabel": "Loss on foreign currency exchange", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r76", "r460", "r519", "r595", "r596", "r605" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r106" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r188", "r225", "r396" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Acquisitions", "terseLabel": "Issuance of common stock related to contingent consideration liability (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r58", "r59", "r84" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan (in shares)", "verboseLabel": "Employees purchased, shares", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r9", "r58", "r59", "r84" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r58", "r59", "r84", "r273" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating lease rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r597" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r542" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r101", "r123", "r124", "r125", "r140", "r141", "r142", "r144", "r150", "r152", "r165", "r218", "r219", "r253", "r296", "r297", "r298", "r308", "r309", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r340", "r341", "r342", "r343", "r344", "r345", "r355", "r412", "r413", "r414", "r429", "r480" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Loss [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r8", "r24", "r323", "r326", "r355", "r412", "r413", "r539", "r540", "r541", "r546", "r547", "r548" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r127", "r137", "r168", "r169", "r173", "r176", "r177", "r181", "r182", "r183", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r339", "r394", "r563" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income Loss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r167", "r174", "r178", "r180", "r495" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payment for tax withholding in share-based compensation", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r132" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock in at-the-market offerings, net", "verboseLabel": "Proceeds from issuance of common stock in public offering", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Stock option expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r506" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "verboseLabel": "Restricted stock authorized and granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of restricted stock award", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "terseLabel": "Unvested restricted stock, shares", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r276", "r277" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureNatureOfBusinessAndOrganization" ], "lang": { "en-us": { "role": { "label": "Nature of Business and Basis of Presentation.", "terseLabel": "Nature of Business and Organization", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r57", "r77", "r78" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "terseLabel": "Number of shares vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r280" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r46", "r47", "r262" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Other Share Based Compensation Activity Table [Text Block]", "terseLabel": "Schedule of Information Related to Stock Options Outstanding", "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award." } } }, "auth_ref": [ "r44" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r105", "r487" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r71" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r81", "r231", "r232", "r486", "r562" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment, net", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r73" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r243", "r254", "r255", "r256", "r257", "r258", "r259", "r334", "r363", "r364", "r365", "r497", "r498", "r500", "r501", "r502" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r243", "r254", "r259", "r334", "r364", "r497", "r498", "r500", "r501", "r502" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeases" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r348" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r243", "r254", "r259", "r334", "r363", "r500", "r501", "r502" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r74" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r353", "r509" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r74", "r135" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value By Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r338" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liability", "terseLabel": "Operating lease obligations (see Note 5 and 6)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r350" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liability Current", "terseLabel": "Lease obligation, current portion (see Note 4)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r350" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r6" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "United States Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r492", "r500", "r502", "r601" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r129", "r145", "r146", "r147", "r148", "r149", "r156", "r158", "r159", "r160", "r164", "r330", "r331", "r393", "r409", "r493" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r105" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 52,858,920 and 49,199,845 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r59", "r399", "r510" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease obligation, long-term portion (see Note 4)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r350" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r59", "r440" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r59", "r440", "r458", "r606", "r607" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r229", "r230", "r464" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Public Offering [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "Income Statement Location", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r230", "r464" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use Of Estimates", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r96", "r97", "r98", "r99" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r346", "r358" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income Expense", "terseLabel": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r72" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Payments", "terseLabel": "Cash paid for operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r351", "r352" ] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Long-Term Liabilities" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price of warrants or rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r252" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "verboseLabel": "Restricted stock vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r505" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Stock By Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r35", "r36", "r37", "r38", "r39", "r40", "r41", "r82", "r83", "r84", "r109", "r110", "r111", "r166", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r423", "r424", "r425", "r426", "r499", "r528", "r544" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Employee Related Liabilities Current", "terseLabel": "Accrued payroll and employee benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Profit Loss", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r102", "r118", "r120", "r133", "r137", "r143", "r151", "r152", "r167", "r174", "r178", "r180", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r315", "r318", "r319", "r331", "r339", "r394", "r405", "r428", "r461", "r478", "r479", "r495", "r507", "r508", "r520", "r541", "r563" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r153", "r161", "r162", "r163" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration By Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Acquisitions", "terseLabel": "Issuance of common stock related to contingent consideration liability", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r9", "r22", "r84" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r14", "r137", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r317", "r320", "r321", "r339", "r438", "r494", "r521", "r563", "r598", "r599" ] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration Type", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r20", "r55", "r398", "r439" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock in at the market offerings, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r58", "r59", "r84", "r429", "r480", "r485", "r520" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan", "verboseLabel": "Employees purchased, value", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r9", "r58", "r59", "r84" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r89", "r402", "r510", "r545", "r560", "r594" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Sale And Maturity Of Available For Sale Securities", "terseLabel": "Proceeds from sales and maturities of short-term investments", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r130", "r131", "r550" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Value Shares Issued Net Of Tax Withholdings", "terseLabel": "Vesting of restricted stock awards including withholding, net", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r22", "r84" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings", "terseLabel": "Unrestricted common stock", "verboseLabel": "Vesting of restricted stock awards including withholding, net (in shares)", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from exercises of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r4", "r10" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r243", "r254", "r255", "r256", "r257", "r258", "r259", "r363", "r364", "r365", "r497", "r498", "r500", "r501", "r502" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r220", "r221", "r222", "r223", "r224", "r226", "r227", "r228", "r244", "r250", "r328", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r407", "r496", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r556", "r557", "r558", "r559" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r60", "r510", "r603" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Sale Of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion Of Stock Amount Converted1", "terseLabel": "Fair value of common stock retired in exchange for issuance of common stock warrant", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r28", "r29", "r30" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par or stated value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r59" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r511", "r512", "r515", "r516", "r517", "r518" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r67", "r76", "r93", "r102", "r118", "r120", "r125", "r137", "r143", "r145", "r146", "r147", "r148", "r151", "r152", "r157", "r167", "r174", "r178", "r180", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r331", "r339", "r406", "r461", "r478", "r479", "r495", "r519", "r563" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Net loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r66", "r92", "r167", "r174", "r178", "r180", "r394", "r404", "r495" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research And Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r56", "r300", "r600" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss, net", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r65", "r113", "r400", "r416", "r417" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL NON-CASH ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r538" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General And Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r69", "r463" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r333", "r334", "r337" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type Of Arrangement [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax", "terseLabel": "Other comprehensive income - unrealized gain (loss) on short-term investments", "verboseLabel": "Unrealized (loss) gain on short-term investments", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r115", "r116", "r117" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from issuance of common stock from Employee Stock Purchase Plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r395", "r403", "r510" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r68" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Asset", "verboseLabel": "Operating lease right-of-use assets (included in \"Other assets\" in Balance Sheet)", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r349" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements Policy Policy [Text Block]", "verboseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unrecognized stock-based compensation expense, period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r294" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r42" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r524" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r61", "r84", "r401", "r415", "r417", "r427", "r441", "r510" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r155", "r160" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of stock options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r282" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Noncurrent", "terseLabel": "Other", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r19" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r154", "r160" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "terseLabel": "Number of Stock Options, Outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r268", "r269" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r104", "r137", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r317", "r320", "r321", "r339", "r510", "r563", "r598", "r599" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-average Exercise Price, Outstanding", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r268", "r269" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r138", "r139", "r242", "r247", "r356", "r489", "r491" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r565" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "verboseLabel": "Number of Stock Options, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r270" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-average Exercise Price, Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r270" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r546", "r547", "r593", "r602", "r606" ] }, "alt_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "AggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate Intrinsic Value, Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r43" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name" } } }, "auth_ref": [ "r138", "r139", "r242", "r247", "r356", "r490", "r491" ] }, "alt_PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Piper Sandler company and evercore group limited liability company and B Riley Securities inc Member.", "label": "Piper Sandler company and Evercore group limited liability company and B Riley Securities inc [Member]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Indefinite Lived Intangible Assets Excluding Goodwill", "verboseLabel": "Indefinite-lived intangible asset", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r80" ] }, "alt_TwoThousandAndNineteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "TwoThousandAndNineteenEmployeeStockPurchasePlanMember", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Two thousand and nineteen employee stock purchase plan.", "label": "2019 Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities And Other Liabilities [Abstract]" } } }, "auth_ref": [] }, "alt_CommonStockValueOfCapitalSharesReservedForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "CommonStockValueOfCapitalSharesReservedForFutureIssuance", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Common stock, value of capital shares reserved for future issuance.", "label": "Common Stock Value Of Capital Shares Reserved For Future Issuance", "verboseLabel": "Common stock available to be sold" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees Current", "terseLabel": "Accrued professional services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Award Type", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r261", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "alt_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued interest and other", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "alt_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r58", "r245" ] }, "alt_IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes and research & development incentives.", "label": "Income Taxes and Research & Development Incentive Receivable, Current", "terseLabel": "Income tax and R&D incentive receivables" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r261", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ] }, "alt_IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes and Tax Incentive Receivable", "negatedLabel": "Income tax and R&D incentive receivables" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r122", "r301", "r302", "r304", "r305", "r306", "r307", "r422" ] }, "alt_ResearchAndDevelopmentIncentiveCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ResearchAndDevelopmentIncentiveCredit", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "lang": { "en-us": { "role": { "documentation": "Amount of research and development incentive credit.", "label": "Research and Development Incentive Credit", "terseLabel": "Research and development incentive credit" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "alt_ExcessTaxRefundPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ExcessTaxRefundPayable", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy excess tax refunds.", "label": "Excess Tax Refund Payable", "terseLabel": "Excess tax refund payable" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Agency Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r492", "r500", "r601" ] }, "alt_EvercoreGroupAndJmpSecuritiesLlcAndBRileySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "EvercoreGroupAndJmpSecuritiesLlcAndBRileySecuritiesMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Evercore, JMP Securities LLC and B. Riley Securities, Inc.", "label": "Evercore Group and JMP Securities LLC and B Riley Securities [Member]" } } }, "auth_ref": [] }, "alt_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for class of warrant or right, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r58", "r440" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r333", "r334", "r337" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r58", "r440", "r458", "r606", "r607" ] }, "alt_PaymentsOfConditionalEconomicIncentive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "PaymentsOfConditionalEconomicIncentive", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payments of conditional economic incentive..", "label": "Payments of Conditional Economic Incentive", "negatedLabel": "Payment of conditional economic incentive" } } }, "auth_ref": [] }, "alt_CommonStockVotingRightPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "CommonStockVotingRightPerShare", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Number of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Right, Per Share", "terseLabel": "Voting right" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "alt_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "OtherWarrantsMember", "presentation": [ "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to other warrants.", "label": "Other Warrants [Member]", "terseLabel": "Other Warrants" } } }, "auth_ref": [] }, "alt_WarrantsMaturingOnMarch122024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "WarrantsMaturingOnMarch122024Member", "presentation": [ "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to warrants maturing on March 12, 2024,", "label": "Warrants Maturing on March 12, 2024 [Member]", "terseLabel": "Warrants Maturing on March 12, 2024" } } }, "auth_ref": [] }, "alt_ClassOfWarrantAndRightWarrantsUnexercisedExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ClassOfWarrantAndRightWarrantsUnexercisedExpired", "presentation": [ "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants unexercised expired during the period.", "label": "Class Of Warrant And Right Warrants Unexercised, Expired", "terseLabel": "Number of warrants expired unexercised" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments And Contingencies." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments Of Stock Issuance Costs", "verboseLabel": "Issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r26" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r77", "r136" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r527" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r45" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r523" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Remaining shares available for issuance", "verboseLabel": "Common stock reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Outstanding", "verboseLabel": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Other increase (in shares)", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r526" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r523" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r561" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r62", "r63", "r79", "r442", "r458", "r481", "r482", "r510", "r521", "r545", "r560", "r594", "r606" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r357", "r359" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r523" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Number of securities called by warrants or rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r252" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r523" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax", "terseLabel": "Unrealized (Loss) Gain", "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r551", "r552" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax expense (benefit)", "terseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r95", "r100", "r151", "r152", "r172", "r303", "r310", "r411" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r31" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Investment Income Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r70", "r170" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r525" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r510" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of Business and Organization" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short Term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r90", "r91", "r537" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Asset Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r500", "r553", "r554", "r555" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r260", "r264", "r292", "r293", "r295", "r505" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r523" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r105" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Long-Term Liabilities", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Shares Issued Price Per Share", "terseLabel": "Public offering price, per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r103", "r114", "r137", "r217", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r316", "r320", "r339", "r510", "r563", "r564", "r598" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r129", "r145", "r146", "r147", "r148", "r149", "r154", "r156", "r158", "r159", "r160", "r164", "r330", "r331", "r393", "r409", "r493" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments To Acquire Available For Sale Securities Debt", "negatedLabel": "Purchases of short-term investments", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r25", "r130", "r186" ] }, "alt_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "alt_BusinessAcquisitionTermOfLicenseAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "BusinessAcquisitionTermOfLicenseAgreement", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Business acquisition term of license agreement.", "label": "Business Acquisition Term Of License Agreement", "verboseLabel": "License agreement term" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "alt_EconomicConditionalIncentiveGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "EconomicConditionalIncentiveGrants", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "lang": { "en-us": { "role": { "documentation": "Economic conditional incentive grants.", "label": "Economic Conditional Incentive Grants", "verboseLabel": "Conditional economic incentive grants" } } }, "auth_ref": [] }, "alt_OwnershipPercentageOnExerciseOfWarrantsWithoutNoticeMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "OwnershipPercentageOnExerciseOfWarrantsWithoutNoticeMinimum", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Ownership percentage on exercise of warrants without notice, minimum.", "label": "Ownership Percentage On Exercise Of Warrants Without Notice Minimum", "terseLabel": "Ownership percentage on exercise of warrants without notice, minimum" } } }, "auth_ref": [] }, "alt_NoticePeriodToIncreaseOwnershipPercentageOnExerciseOfWarrants": { "xbrltype": "durationItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "NoticePeriodToIncreaseOwnershipPercentageOnExerciseOfWarrants", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Notice period to increase ownership percentage on exercise of warrants.", "label": "Notice Period To Increase Ownership Percentage On Exercise Of Warrants", "terseLabel": "Notice period to increase ownership percentage on exercise of warrants" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "alt_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants.", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r523" ] }, "alt_EquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "EquityDistributionAgreementMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Equity Distribution Agreement.", "label": "Equity Distribution Agreement [Member]" } } }, "auth_ref": [] }, "alt_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "At-the-market offering.", "label": "At-The-Market Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r314" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable Gross Current", "terseLabel": "Accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r112", "r184", "r185", "r488" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Schedule of Short Term Investments", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "alt_ChangesInEquityAndComprehensiveIncomeLineItemsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ChangesInEquityAndComprehensiveIncomeLineItemsLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Changes In Equity And Comprehensive Income Line Items [Line Items]", "label": "Changes In Equity And Comprehensive Income Line Items [Line Items]" } } }, "auth_ref": [] }, "alt_OwnershipPercentageOnExerciseOfWarrantsWithNoticeMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "OwnershipPercentageOnExerciseOfWarrantsWithNoticeMaximum", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Ownership percentage on exercise of warrants with notice, maximum.", "label": "Ownership Percentage On Exercise Of Warrants With Notice Maximum", "terseLabel": "Ownership percentage on exercise of warrants with notice, maximum" } } }, "auth_ref": [] }, "alt_ClassOfWarrantOrRightIssuancePricePerWarrantOrRight": { "xbrltype": "perShareItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ClassOfWarrantOrRightIssuancePricePerWarrantOrRight", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, issuance price per warrant or right.", "label": "Class Of Warrant Or Right Issuance Price Per Warrant Or Right", "terseLabel": "Purchase price of warrants issued" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r291", "r299" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r346", "r358" ] }, "alt_PaymentsOfDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "PaymentsOfDeferredOfferingCosts", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payments of deferred offering costs.", "label": "Payments Of Deferred Offering Costs", "negatedLabel": "Payments of deferred offering costs" } } }, "auth_ref": [] }, "alt_StockIssuedDuringPeriodShareExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "StockIssuedDuringPeriodShareExerciseOfWarrants", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period share exercise of warrants.", "label": "Stock Issued During Period Share Exercise Of Warrants", "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r523" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted-average Remaining Contractual Term, Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r85" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized compensation cost, stock options", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r592" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r346", "r358" ] }, "alt_CommonStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "CommonStockTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStock" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of common stock.", "label": "Common Stock [Text Block]", "terseLabel": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted-average Remaining Contractual Term, Vested and expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r284" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r592" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r346", "r358" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r48", "r49", "r311", "r503", "r504" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "alt_CommercialPaperAndCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "CommercialPaperAndCorporateDebtSecuritiesMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "documentation": "Commercial Paper And Corporate Debt Securities [Member].", "label": "Commercial Paper and Corporate Debt Securities [Member]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "alt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental balance sheet information related to Operating leases.", "label": "Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]", "terseLabel": "Summary of Supplemental other Information Related to Operating Leases Balance Sheet" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurements, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r332", "r338" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r311", "r503", "r504" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r522" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "alt_AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis", "crdr": "credit", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Assets or liabilities that were measured at fair value on a non-recurring basis.", "label": "Assets Or Liabilities Measured At Fair Value On Non Recurring Basis", "terseLabel": "Assets or liabilities measured at fair value on a non-recurring basis." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r346", "r358" ] }, "alt_AccruedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "AccruedResearchAndDevelopment", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development.", "label": "Accrued Research And Development", "terseLabel": "Accrued research and development" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r332" ] }, "alt_SpitfirePharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "SpitfirePharmaIncMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Spitfire Pharma, Inc.", "label": "Spitfire Pharma, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r140", "r141", "r142", "r165", "r390", "r418", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r459", "r462", "r463", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r514" ] }, "alt_SalesMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.altimmune.com/20230930", "localname": "SalesMilestoneMember", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales milestone.", "label": "Sales Milestones [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]", "terseLabel": "Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r11", "r52", "r53", "r87" ] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities Table [Text Block]", "terseLabel": "Summary of Other Long-Term Liabilities", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r31" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par or stated value per share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r58", "r245" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r140", "r141", "r142", "r165", "r390", "r418", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r459", "r462", "r463", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r480", "r514" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Stock options granted, weighted-average exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r272" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure", "terseLabel": "Total", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r52" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r161" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r134" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r134" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r74", "r75", "r76" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Stock Options, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r272" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Investments Fair Value Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r333" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r13" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r536", "r543" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Noncurrent", "totalLabel": "Total other long-term liabilities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r108" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r54", "r94", "r126", "r171", "r347", "r465", "r519", "r604" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1", "terseLabel": "Change in fair value of contingent consideration liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r313", "r542" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r244", "r250", "r328", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r407", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r556", "r557", "r558", "r559" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "lang": { "en-us": { "role": { "label": "Available For Sale Securities Debt Securities", "terseLabel": "Market Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r189", "r225", "r391", "r549" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r528": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 59 0001326190-23-000047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001326190-23-000047-xbrl.zip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
"RD^-?E;I.KV'0K%,R\)Q"K>I[KCS=MYZ5'\5),-$H0@SO&>XARODB!\4K(7SH=S)R/R M)(B5]",V&QBVJ"SGK(P@15P?$($Q".!GKY'/;UN0O#'>KK3EG:B^_I 2MSV M,!JSLX'G%WIYB'(&];3F]C/ <6].<5]E03@CQ67I0UYF4R#D=T/S+Z+LE"W MTRT4-^\@A=VPX@(]!7IZPF_'^MI:]M#H&'KE, 03SBV+:&K:V0ZVEQ7II! M[CC#]\V._)SD YD]$#>[W;C9G9UQ[GK[3#/SJRO/%0M/NOH,D!G0A!_XA#:$ M4=]%Y^R<;J^0-$.QXH[Z!YJ^KV.,0-6!JK^RJE\[%O#3JMZ7T9E$B^I$"IB] MDZ[3;23M"U4G4&3?87/>9#W\1#QA-W97N U4'JO[JG[MB,1/J_HT5%"?D;:)9)DM4>%6 M+---"S-?A"8>\!=O+[J]TH#G2XT?:IY^N>9Y[QOWM.M". A%<[A9RKZ\CW M_\/57P_U+J:#X4QAZ!C&V5AI4J;8'K9GB&%1$<",]4'J@]%6/4ORRTB?U MO;K26H<9API3AE^)O-H;L MGHYA,A(ROC!!FZ?,' 7RZ^B?.49Y,S M!YH?66T_LJGIW]5Z]-V?;3JV3H& MDX0^EY,)&QP0(=?Z(H!!OW1'XHV75GQ]$?TK!#8J,_/Q6;?&B'>.';[UM.O M!D"^2D3D5[ 1F\1SQ$:]GATPS93;S$9S_I#"/Y8KD&^U4#Y'$ 5@"LN.E MRJ]@Q=+N9>Y3,./A9+ER3F9S985+-L><[T'=E]8<1N1E>II#P"/"H#'J\1? M?@4\^JLV.Y2T7@_N4P01&<8,Q+D=I;JC@YOVDQS4GO[5>U3-^ MZD\AFE@Y7+!7X'M$O'N"KTJYNS=_,<73O9NMT'<;V3@L+\DXRG]J&%$O-/%, M-\WUD#O$H99"\M3PF,WUMTH0[1\!J'O. 6F?2J@^^Y%GJ(G3:]?:-EM^GA MPNA&?7>9KA&%+==P \D]>(Q/Y"" @#P;@#@VJ=61Q0 M4-SNCSV@SU2GWL_='^=7=#\%/)[NXZS]H>J>;ECQ)< .E: /#=1(%SL4!0 M<\T4(MWK!;W&8_(G(K'I$C];/Q>[.:UU^M3995G"N-HT7#UYHTG\H(651C M,.7S]Y?;-H!B#( AMX\AP+0"M0!J\4[V];]D6E/8;H7H<;>TK>&,739'$ZKZ,\T7;>KOE!Z#4 (05WU-8\74.8^CQSW7YE))Q[TA@]LXFE]["Z6T7 M8]\91J&MD.YBGNT_D$Y&U M_W1NX#&,F:U^J&?S.>GKFJE87NV/?)/_KUHF%]'&#V,HUD,W^YNGBT OM_^O M&M W!/$/:MTWNKUKL5L? D/G\&5W2N6HZB.WO)#,0-74=>2T(HM/6+7V^2, M!AD:\T;FCCUW][=K#590AWU9N7 9;O>GBD10>#G:7S,!\(8R8VVG!;3G.$R6L;\&L>D@"U#0!T;A]T M[NRBB2LZ,T8HU@><7^]+[14&$5Q=6ZIJX[S+1 MWLSSHR"1 9643LXH#@\T!;RD"P@)H]7H>05@E5OJ2%?<1,4EESV%F4L0X.U MGV1"60DT_.>U;E!^@WE6!/9>)3KT#.(](5GVDY/DW!W[83X@-HY#2TWB' BG M_J\?<)LD>)M/VD9V9M%5C!Q]T)3ZC+UH#-$>-<5D,2Y8M&;PBHJPEXMY[ZHZ--%I#L]K$4;)=0?:JH265HM M$Y/:VG26%^#,J%7#H!7#$R_XA,4Z1ID': SDSYVBO_)N[NV\@4):6&'XBJ MUI\L#']]F__U@C//^8/RGB:P8ES_B;5.(R%_H)YX)30RY@8C?50S(=8 MSZ&J#/+PYVXW)+XPR6/3DI25U"?7=&/=WPK9T/)85+:NU]Q7 K2[5[1C0T3N MQ#-K;+>WHX,--U.=VK( [=X?VOUR".ZJ:-==C_NP('DS.$ .Z0_(V++=". MS-$.I^\+[6XCL%9!1?J;\+?9[F<#;[L^PGUBQ:N[7@1ONB: ORJ)^Y7A[W?# MAU>%/T+40ZF!)K1DL7:'V)BCS0%A<_C+[O^1%Z\5O/VX ^@W:N@'63VU2X7 MVA&GSS2?,2;U>3(4 -J]/[3[Y=#G5=&N$Q'F?J%CK)7J?)_1+V>-XZQ>A/VX<#Q9\Z&&AT0,[UP0 _^!=1[4FKVK-.CQ%7U MD#<!(SXSRK]A(;?@N"4BP]FU#YJMFZY8UYU>/ZTSG:\2'$R$7L@,>P!(_#K MU?0#/ !X\+[PX)=#7J^)!ZM#=QXUD'XD_7%-!8[ZL"V"SP@/_R%,P\H33X0 M6+G^]&;PX#9B7F^M,P @W@(@?C #PH%IX\,MAD]?$ W;)=X_[%4Y\V9C028G&4-F M!1[D412<>!IY(' 7P$(I3R[Z(.[0I+F)\[M(SC^2O+R_0T_OBU2'^KV.?? M?#I-BF84/ZGK%Q^\IN>%>%^-'2/+^IB/\0FBK_&< Z6G'V."W[[72CUQ0M MOP-+\8[9JM8\/\[&EJUU+9N_E;W,#!6GME/"N.8;M3@C3SPE66<:N\YEM#A6 MJ^0_&):G>)J5$6<2$NO%=5A_9HM\249\?XF^#.^JOK/^Y05:6]'.48ZY1.K_ M^;5!.I:G0YOSNW]BE,5T/@6I?V/,_UY;^[_^F_WS]%C-T94P1]/-?[X652Q_ MS1.6PO][%41\E,C'2:/XDT7X)(#H%X,N_OV?__?EX#^'RB'-=_SPXQ.J?S&K M1^:B!<";.J2&NF)#BI&]^/BI,HQ>IPEQ?R)/1F,CY\, U:H1&9,B/^M??$Y M9T>)EZYR@+[@V,]@1S=B#^2?V+DYZ\4_#TG1]9.8A]#'4G@^J]GC_[RZ=F M:_(X"1++WGVE9?D&!;#/B_!?I;8)%8J?Y@LF>9XG(- WMCO?-G= MHTPJ/R.77[/U.7Y=&R-^4KV4PI+)Z_7:,'1$DV%:@66<8G19Q3!%5E ,IV$< MTV$&^W">_&4&7H#[RK9>6[L8-H=#J41]W!VN+JCQI]?3#!CT1^T&VR4ZXI M3K-_A]QHOM1H<=M3FQ.Q(S2>AW^#>=PY>#K'T>98UOU1['6>N.:H\C'32Y MB5CZO!M^=6A_R$]V<%_O=4HOC7U?W2]S$+[291Y:-%#33]H M>O:[PM&L6X&L7'TKR]%74QG%!Q1<8-"I=Q!5=EU< T62$PAM 1G:9AY5$\ ME$_;O>XX["#[%LDU-,4C)-$UZVF:>Z;8MZ1->R#%;KR9P?.Y%T2.K^P&>BJC M,O4M)25/!/AT,J:VV-GKFMB'3JTT\QF?>:B(4'Q=1T.X[F5SJZF\_H.+TC) M;TF#\!<7NB+;$Y:6E2O2Z:FE!'@3D%)S8(?S)HBF!EO#RIKK"? MR.F&/\%'H[_VQ+T5F&E.B7]+.1/'!9> M"Z/GDMB=3C$";]?G'3.C+$\_JK/U8]189OT2-U$ZGL6G>8/+4_?WS<;$DZ2 M.$=VQR=N-Y[WT:.0DY:F/S7A^7"N$Y04K ]VO[$_DO!D FY]'[.YB;:";4 M)5Y@Q/T\5D:"F5.6IF]OIEN.7N,G+FDNJ'8HM)MQEB//U>RQM)@[6O2 UL M=L3KHY.^--,LCS]1FBWI!W<)C@2.\ZMX3W''3[EP9$,U$XJD^7IUW?-2=,;DV,X"+G5' ^G M&Q5E,\J2G&S(UHKHBHX,]QL#$JUO_&9OEE,2I6>2_60\6BPB#IUWX S.M,'X ME+\=0;XEM4:ST-T'K;I]'$AAO8ZZ._J0/Q0IL7^[6IY6033927->/RZ0P13U M%F:&":4Y\7P2+2TQ0YUDY>@#-K$:O5#($LC7293U\[@.(;%Z7%P( ^-]:J5 M/[,\TO70TNMUZY# J+;0@\,8(VDOS4E+(UW9/:4/5G,V8RR--(059RI'PY25E#$TSY18LY<\LC]3# MT.D0VRNL+:Y[7251='D0Y0\MC_2HN)Z B&03YM>,N>P-)MZV;LI,>:3LZ+#M MZS(QL0/%2SH0+$W3O9!1ED8J+%!Z'$B&:3=F"L](D<^LLCDQSXS4E5HJ'%I2 MQM-.MTNFQDR=]@O2TDBC9FN/Z2T!@QOMX4KV,:3GC85,HK4A)N(B6L%:4FF=XC7@>JAYMCM=;VY5A,-GH[8G+0TK>82H[06R?0EQ6C5 M=_.A,F8P,R>EOR4E-QV%"1H.!;=YOQO4.W-.S9/=="4W MF7WS4)"6YK60IU.J<;(,VTWHQCX(1^9N;.:DY7DAE'^@CM.8FQ@_5D[T7Q3)!W&8"AY7EY_FO"Z,-)(GT7F@I..UQPXT M]%06.HR4_NO^ 01)S#)SCO>("5F4#IFZ2)S,.9=-0WUE9HNWMS5I"6%I<)M-[> M/>X:-H\-N@-H":_GE)"3EOC5X>ML!Z;UJ6VYLI/.F9'6[!5/+K9N+;2E:N3)@ M!9DO5ZC79^E6="6=(%<(L1,QXY#3MR:;HL\$6GS/+'R,@1==(_7Q]L(SK>D M^R23:B-E%B/D2[9DY:&BW=%YTV%W8Y6->L"3)?'.>(F>:D MY='&FY4V&8J92XJJ$X'&T?4>3MB"MC1:"6JK];7L3CC]U.YT;&4I8TG1[^, M"5"=[:9&=UQ0D&2,E].EXK#^B>CZ,Y;FEC. MG 6BRW.I/9FO<&_"=-Q^\=02UJF,("P&AXXOD;-NHE"LW:21XJEE'O399+U9 M-HX$;,TBT?9V@WF_6S0V:OY3Q3AJJ;DKZED'6[SZR=3M%0H30OPEEM:ISV&)\VDF( I7DMY W.=#L]ESM. M<%;G^,6P"Q>-E)Y9+Z+CKWU$:L');-F7=SVG$6V+NX'+FQAIJXP3CZY+_3FF M'0^T,[;F9DY:>FIO>M2XIEMO<_-)9GTA>&=X3D%: AJQX0^A)1;3G+X(0Y3O M=:4.7@R@##3"="],L$YR@/5.G$2&.3BT5+:@+8&'/8M=P5%C T:[&);?&-C? MF^?GE@ A/ P\.3VVIG9_-6U9+M-=8DIQOT79\8!6$4,%=<.>KT38FTQ[D)\4 M]V^5%E= R(<$O3!%JT=%Y]0[>A:Q1GX,K^B\;X5#?&6-'?L<7VO+O@U)^2D M91]E@C5W<4S-)#V@!BAK+?9'H2 ML=9F.PO1"12:FS/;P1!C^=B'BFD]LT7C M?.+47=$;[NCC>\?'U%1/B\>6=6&&3HR)P/ [3I\--K[8JJM]Z?SL"9^:D)>82QPT?U9MR M+7UW2';+TQ/D%4\M&E9DY:&NW06R=RCV4P&#(E M=>I)AVZ7NIQRJ--7)_O>NY#+OPRAWL2'>O\&E!6QJM[)^F)-88(+".6>,( M<_H6U\IHG_'K3LQ6;T^C_ABV,O,8&!C"$0,V)RV-=H>,3AUTW8]LK<2,)&_4.$5<>R_)C-U)<($O1E >K;U@1FL'WLPD5V_P"Y;O3KNK M[+G/.&##=3#LHTC8AE%^-N\S^[H<9+MK]!D';+;3>0:5M:&M. 6YK59N'(WW"YY.%@TDD(1SK%\IAA >;W<2&VJDB[BTE&"QT$;M[LCQO!,_Y,PYGX,3V6 M(5M9#0<3LRH2U M!(5TCHG3@O8)OHH\]J=LU[F60?,=1]E%^L>G#U_&@?-\[F.R$^;:.=TR]>I MJ"]J'1X34>547QP^O?7Q:<@Y)_3!Q20/_$76XU]D>CYXOE^]DS#\=.G%,O3 MSU!>U_'QG+A+,R;\,&7VF,(L7OQ$JJB1GY\^>(WDV??K?+[XNY^O!/@B__FW MX 0 JQ+]=:%_A-]\4 /6)>W61?X3X8!ZP+6!:S+SZT+]2?U8EM.L"[ [H-U M 3A6]76A_B3!NE1P70".57-= (Y5NPY+;$Y$?IGXKQY&T$!T NT4+N(KOD2= =8#J -4!JO,M2S3? MR;\L[OC^7:?_RB)#_[K$J%^]\TOV?/B+U;3$31REN$U;O7L! 5 H/32/ '! MHKN""! LJHJ8@& 1,"T@6 0@%[CM9;<]&UV>=5. JD(4?R,+4CTLF%NSWZ<#](\8\-(:GV\N+O]; H!/XH__ MKO@C]+>=))#=H5;<7_\:C20NK!R-]UH4+L,D^ZV'TV!P!^,P5%_7* M<^"<$KL?=_GQ"2%CIW-@;A!6H4H^^6Q85MFB4M]R,J#667 M-](#L@)DY8>RTM0-2[, K@!9^;&L#/SH4KX$)1[%A0N2#+F76[][D+Y\=_ M:)JN&\;;"LU+LZXKCN)I>DV):TU=T_/^Q.=( (8\MD+,VR)?5(&JQIXO=>HU M-X2OSX:W[KW-1C)OY%V L,?6VX]]LO.'G;LJ4>9T:SQO.DEE]U:V[.VK]0K_N4F/N9WIR4_6#O8K[ M(];F^^[(6"U[K=,L[W"7=^1F'A"&>:!QXH6.W']SK_SNU>?-V/"2^I3X\L^+ M5816;:_#122V)3IU"!3;C6;2.T6M$Y'IT%GBIAOCA(0]BL@\460^#R23RB! M?4()EH8U;H^B&!T.';;VG!9-_2\#R7QX:^K@ .PK>\.',CJS;3JX/"YWCA/ M]'>]QZC3(U!H(RH<&U:[93>L<;K5V4$@(E<&BIV$+5=6SU4ETICLD-EIL&KV M\M:Z= 84)/V ,0R "P 7]PD7I9G6_J@67DST6+$\?EF@R!B6/>89Q(CK2M=5G;[+H>3$X(T]O$V4HL4U\N$O MC(>:!HO0<:_ &8 S "8\2H^QN?:L:("_ZL"HJZG^:[^""/QN$-V( +N<_W^ MB(EP8=OD1.&58&0U1(<-0S80>!XA8= -%LNA8\KGGK3$ XI2 $0 B-PIB+S^ M/J73V\_LQ0G:VJC%-[3^8>ICWH5U_5L5YQ:S/;N;8"[7'[!+2EC>M(M5)SZ M\!="9TK.8"]L+FZIV(TL7E%P!552,\S7.XNPUPEG]1=)/^>J=#\._F':JE? M46V)7F)V;U]1=K&%>O6#NS^V"]O5_]6H17E=8[@A4@K6]QKOSU79MF$A9& M54;DPK?!YDO8X^.#G;1@&P=935].U9QSO5::P,+^3;#F+_M-+'K;1+%^9BB MJ?^=-Q7@7?2"I^:" @ 4 $F$$@KD%8@K4!:;TE: M7]=A6Y/">#[1)W4N():<.,(5K-'[_636&SA9/8,>VJI2-VS1[QVU,#GH(RMW MLO(XUX^\K!NO\3T'OKB#'FI6I-=\(WN7K]DU?Y?/,[K7B/V%@V'W$I[^A6+< MBV[CRD5W';%+2IJID'#;L2V5%W7=:9M_HS0W?W8WBA)]G8T\6XTS.IPK=HM? M\F>)?U%]3.UNT)R6C#2<-R&H?WRV+8[5KP4YG:W<1Y@PJ'WUZNYQ6] MB(HI4"4%S(S2'_XBD7=3K@JP!6 +,% S(&8 S$'8GXO8G[3P==+>'<" MGG@+&[-#SEWB!]C<18&OFYEWET=37W3O;J]@<9',LY MK'H&DI$>\\;YBY8?3I7#_+,>1,\$61?4JLTZ@[$EZ1-NM80W;9P]I3=!UD) M_ '#RP<+;B:962U- @E<4!\Q/I>Q?JMZQ)3+CX0;O;C:)^8R[/_O6W-K-L MK][&&^K$>O)>.D>.(O )O5ZX'H"G-M,^L-?^%6/\P)H = "+"80:R#60RK MMJ) K"LAUF_N"%XX2'IIYXU?MHZCT6&]@/O=W1$;<2U6&[9\Y8'3'_@O=U% M]6G.MN(66=_(CUWGS=3.(50C]-T:Y^X<_ZCKYP9KM7$2:ALETFMC1[G
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�XDY,H M64P=UCB!+1:
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end